

EVIS SALA, MD, PhD, FRCR, FRCP

Curriculum Vitae

GENERAL INFORMATION

Office address:	Università Cattolica del Sacro Cuore and Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168, Rome, Italy
Phone	+393382047672
Email:	evis.sala@gmail.com
ORCHID ID:	https://orcid.org/0000-0002-5518-9360
SCOPUS ID	7004450805
Languages spoken/written:	English, Italian, Albanian, French
Gender:	Female

CURRENT ACADEMIC AND CLINICAL POSITIONS:

Professor of Radiology and Director of Radiology Training Program, Università Cattolica del Sacro Cuore, Rome, IT
Chair, Department of Diagnostic Imaging and Radiotherapy; Director of Advanced Radiology Center, Fondazione Policlinico A. Gemelli IRCCS, Rome, IT

EDUCATIONAL QUALIFICATION

2003	Fellow, The Royal College of Radiologists
2000	Doctor of Philosophy in Epidemiology, University of Cambridge, UK
1998	Master of Philosophy in Epidemiology, University of Cambridge, UK
1991	Doctor of Medicine, University of Tirana Medical School, Tirana, Albania

LICENSURE AND CERTIFICATION

Licensure

Ordine dei Medici (IT):	69258
GMC (UK):	5203135
NY (USA):	265060
NPI (USA):	1962760629

Professional Certification

04/04/17	The American Board of Radiology, Certificate 70001
04/20/05	The Specialist Training Authority of the Medical Royal Colleges, UK, Certificate 203135

PROFESSIONAL MEMBERSHIPS

2022-present	Società Italiana di Radiologia Medica (SIRM)
2018-present	European Society of Oncological Imaging (ESOI)

2007-present	European Society of Urogenital Radiology (ESUR)
2006-present	International Cancer Imaging Society (ICIS)
2005-present	European Society of Radiology (ESR)
2004-present	Radiology Society of North America (RSNA)
2003-present	International Society of Magnetic Resonance in Medicine (ISMRM)
2003-2012	British Institute of Radiology (BIR)
2000-present	The Royal College of Radiologists (RCR)

HONORS AND AWARDS

04/2024	Honorary Membership, Japanese Society of Radiology (JSR)
11/2022	Honorary Member, RSNA
09/2021	Fellow, Royal College of Physicians (RCP)
11/2020	BIR Canon Maynard Award
06/2020	RSNA Honored Educator Award
09/2018	Fellow, ESUR
11/2017	RSNA Honored Educator Award
01/2016	Radiology Editor's Recognition Award "With Special Distinction"
05/2015	Fellow, ISMRM
04/2014	European School of Radiology (ESOR) Tutor Certificate of Appreciation
11/2013	RSNA Honored Educator Award
05/2013	Fellow, ICIS
2011-2013	Journal of Magnetic Resonance Imaging Distinguished Reviewer
10/2011	Honorary Member of Spanish Abdominal Imaging Society (SEDIA)
03/2011	European Congress of Radiology Certificate of Appreciation (Panelist of the Imaging Interpretation Quiz)
03/2010	ESOR Tutor Certificate of Appreciation
2007-2008	ESOR Tutor Certificate of Appreciation
09/2004	Phillips Travel Bursary, Royal College of Radiologists, UK
09/2004	Parke-Davis Fellowship in Biomedical Sciences, Cambridge, UK
09/1997	Honorary Cambridge Commonwealth Trust Scholarship
09/1997	Overseas Research Students Awards Scheme, UK
09/1996	WHO Fellowship in Cancer Research
01/1992	WHO Fellowship in Cancer Epidemiology

EMPLOYMENT

Previous Academic and Clinical Positions

10/19-09/24	Honorary Professor, Division of Medicine, University College London, UK.
01/18-08/22	Professor of Oncological Imaging, Department of Radiology, University of Cambridge, UK. Honorary Consultant, Radiologist, Cambridge University Hospitals NHS Foundation Trust (CUHNHSFT), UK. Co-Lead, Advanced Center Imaging Program, Cambridge Cancer Center (CCC), UK. Co-Lead Integrative Cancer Medicine Theme, CCC, UK.

06/15-12/17	Professor of Radiology, Weill Cornell Medical College, New York, NY, USA.
08/13-12/17	Chief, Body Imaging Service. Memorial Hospital for Cancer & Allied Diseases, New York, NY, USA.
07/12-12/17	Member, MH, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA. Attending Radiologist, Memorial Hospital for Cancer & Allied Diseases, New York, NY, USA.
09/08-06/12	Specialty Teaching Director (Radiology), School of Clinical Medicine, University of Cambridge, UK.
09/05-06/12	Lead for Gynaecology Imaging, Addenbrookes Hospital, Cambridge, UK.
09/02-08/05	Clinical Lecturer, Department of Radiology, University of Cambridge, UK.
03/00-08/02	Specialist Registrar in Radiology, Addenbrooke's Hospital, Cambridge, UK.

Post-Doctoral Training

03/05-08/05	Specialist Registrar (Resident) in Radiology, Department of Radiology, Addenbrookes Hospital, Cambridge, UK.
10/04-03/05	Research Fellow, Radiology, MSKCC, New York, NY, USA.
03/00-09/04	Specialist Registrar (Resident) in Radiology, Department of Radiology, Addenbrookes Hospital, Cambridge, UK.
01/93-09/96	Specialist Registrar (Resident) in General Surgery, Oncological Service, University Hospital Centre, Tirana, Albania.
06/92-12/92	Staff Physician, Oncological Service, University Hospital Centre, Tirana, Albania.
07/91-06/92	Internship, Oncological Institute, Tirana, Albania.

CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES

Teaching

2024-present	Diagnostic Imaging in Clinical Oncology, Integrated Course in Medicine and Surgery Program, Università Cattolica del Sacro Cuore, Rome, IT.
2024-present	Introduction to Diagnostic Imaging and Radiotherapy, Integrated Course in Medicine and Surgery Program, Università Cattolica del Sacro Cuore, Rome, IT.
2024-present	Diagnostic Imaging and Radiotherapy in Hospital Residency, Integrated Course in Medicine and Surgery Program, Università Cattolica del Sacro Cuore, Rome, IT.

2024-present	Diagnostic Imaging in Surgery, Integrated Course in Medicine and Surgery Program, Università Cattolica del Sacro Cuore, Rome, IT.
2022-2024	Radiological Anatomy to 2nd year Radiology Residency Program, Università Cattolica del Sacro Cuore, Rome, IT.
2022-2024	Urogenital Radiology to 4th year Radiology Residency Program, Università Cattolica del Sacro Cuore, Rome, IT.
2022-2023	Oncological Imaging to 1st year Radiotherapy Residency Program, Università Cattolica del Sacro Cuore, Rome, IT.
2020-2022	Oncological Imaging in the Era of Precision Medicine, Lecture to Medical Students, School of Clinical Medicine, University of Cambridge, UK.
2018- 2022	Morning Tutorials (1:4 Rota) to Radiology Residency Program, Addenbrookes Hospital, Cambridge, UK.
2012-2017	Body Imaging Fellowship Lecture Series; Teaching Weill Cornell residents and MSKCC fellows during daily readouts in plain film, CT and MRI; Weill Cornell Resident Noon Conferences, MSKCC, New York, NY, USA.
2007-2013	Summer Clinical Oncology Research Experience (SCORE) Program Research Mentor, Office of Faculty Development, MSKCC, New York, NY, USA.
2002-2012	Cancer Imaging & Imaging of Endocrine System, Lectures to Phase 1 and 3 Medical Students, School of Clinical Medicine, University of Cambridge, UK
2005-2012	Course Organizer (Genitourinary Imaging) & Morning Tutorials (1:4 Rota), Radiology Residency Program, Addenbrookes Hospital, Cambridge, UK. Radiology Evening Tutorials (1:6 Rota) to Medical Students, Addenbrookes Hospital, Cambridge, UK.
2005-2008	Imaging in Gynecological Malignancies, Annual Lecture as part of The Gynecology Oncology Residency Program, Addenbrookes Hospital, Cambridge, UK.
2006-2007 & 2001-2002	Anatomy Supervision to Medical Students, St John's College University of Cambridge, UK.
2003-2005	Imaging of Acute Abdomen, Annual Lecture, Surgery, Residency Program, Addenbrookes Hospital, Cambridge, UK.
1995-1996	Lecturer in Cancer Epidemiology (part-time), Medical School, University of Tirana, Albania.

Tutoring

2007-present	Tutor in Genitourinary, Oncology and MRI, European School of Radiology
--------------	--

2007-2012	Final Radiology Exam Revision Course, Royal Free Hospital, London, UK.
2008-2012	Final Radiology Exam Revision Course, Addenbrookes Hospital, Cambridge, UK.

Mentoring

2022-present	Mentoring of several junior faculty, fellows and residents, at Università Cattolica del Sacro Cuore, Roma, IT. Supervision of Doctoral Students, Università Cattolica del Sacro Cuore, Roma, IT. - Camilla Panico, PhD in Radiology (2024-present) - Silvia De Vizio, PhD in Radiology (2024-present) - Marika Vagni, PhD in Radiology (2024-present)
2018-2022 & 2005-2012	Mentoring of several junior faculty, fellows and residents, University of Cambridge, Cambridge, UK
1997-2022	Supervision of Master and Doctoral Students, University of Cambridge, Cambridge, UK. - Tanvi Rao, PhD in Radiology (2021-2022) - Syafiq Ramlee, PhD in Radiology (2021-2022) - David Hulse, PhD in Radiology (2020-2022) - Ian Selby, PhD in Radiology (2020-2022) - Cathal McCague, MD in Radiology (2020-2022) - Maria Delgado, PhD in Radiology (2020-2022) - Marika Reinius, PhD in Oncology (2019-2022) - Paula Martin-Gonzalez, PhD in Computation Biology (2018-2022) - Stephan Ursprung, PhD in Radiology (2018-2022) - Edward Lawrence, PhD in Radiology (2010-2013) - Andrew Gill, PhD in Medical Physics (2009-2012) - Victoria Jardine, PhD in Radiology (2003-2005) - Lulit Solomon, MPhil in Epidemiology (1997-1998)
2012-2017	Mentoring of several junior faculty in Body Imaging Service and Research and Oncological Imaging Fellows, MSKCC, New York, NY, USA.

Clinical Care

2022-present	Clinical reporting of CT & MRI; Gynaecology Oncology multidisciplinary team meeting (MDT), Urology Oncology MDT; Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, IT.
2018-2022	Clinical reporting of US, CT, MRI, PET/CT & PET/MRI; Gynaecology Oncology multidisciplinary team meeting (MDT), Urology Oncology MDT; Prostate MDT; Oncology Clinical-Radiological Meeting, Addenbrookes Hospital, Cambridge, UK.
2012-2017	Clinical reporting of CT, MRI and PET-CT; Gynaecology Oncology tumor board weekly meeting; Pelvic Reconstruction monthly tumor board meeting; Urology weekly Grand Rounds, MSKCC, New York, NY, USA.
2005-2012	Clinical reporting of US, CT, MRI & PET/CT; Gynaecology Oncology

MDT (weekly); Urology Oncology MDT (bi-weekly); Emergency Oncology Clinical-Radiological Meeting (weekly); General Urology Clinical-Radiological Meeting (bi-weekly), Addenbrookes Hospital, Cambridge, UK.

Leadership and Extramural Activities

2025-present	President-Elect, ESUR Member, Translational Advisory Board, German Cancer Consortium (DKTK), DEU.
2024-present	Expert, Comprehensive Cancer Infrastructures for the European Union (CCI4EU). Member, ESR eHealth & Informatics Subcommittee. ESR Executive Council, Vienna, AUT. Member, Scientific Advisory Board, CRUK Cambridge Centre Women's Cancers Programme, Cambridge, UK.
2023-present	Coordinator of the International Relationships Committee, 51 st National Congress of SIRM, June 20-23, 2024, Milan, IT.
2022-2024	Member, Commissione Programmazione Didattica for the Faculty of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, IT.
2022-2023	Member, Steering Committee, The Centre for Human-Inspired Artificial Intelligence, University of Cambridge, UK.
2021-present	Member, Research Committee, ESR. Chair, Research Committee, ESOI.
2021-2024	Treasurer, ESUR Member, Radiographics Women's Imaging Panel, RSNA.
2021-2022	Member, AWS European Clinical Advisory Group. Member, Faculty Board of Clinical Medicine, University of Cambridge, UK. Member, Steering Committee, The Cambridge Centre for Data-Driven Discovery, University of Cambridge, UK.
2020-present	Member, European Congress of Radiology (ECR) Programme Planning Committee.
2020-2024	Member, ISMRM Awards Committee.
2020-2023	Chair, Social Media & Communications Committee, ICIS.
2020-2022	Member, Postdoc Matters Committee, Postdoc Academy, University of Cambridge, UK. Member, Research Leadership Program Advisory Board, University of Cambridge, UK. Member, Scientific Advisory Board, Leeds CRUK Centre of Excellence for Radiotherapy Research, UK. Research Consultant, Amazon. Founding Member, MedIAN network. Expert International Clinical Reviewer for the Irish National Cancer Control Programme (NCCP), Evidence-Based Guidelines on

	Diagnosis and Staging of Prostate Cancer.
2019-2024	Member, Genitourinary Scientific Subcommittee, ESR.
2019-2022	Member, Finance Committee, University of Cambridge, UK. Member, Clinical Excellence Awards Committee, CUHNHSFT, Cambridge, UK. Member, Wolfson Brain Imaging Centre Management Committee, University of Cambridge, UK.
2019-2020	Co-Chair, Oncologic Imaging and Therapies Task Force, RSNA.
2018-2022	Member, Disease Oriented Team for GYN Cancer, Cancer Moonshot APOLLO program. Member, Board of Trustees and member of Scientific Committee, ESUR. Member, Executive Committee, Cambridge Cancer Centre (CCC), UK. Member, ICM Management Committee, CCC, UK. Member, Joint Steering Committee, Mark Foundation Institute for Integrated Cancer Medicine, CCC, UK. Member, Advisory Board, Centre for Mathematical Imaging in Healthcare.
2018-2019	Chair, Affiliated Sections Committee, ISMRM.
2018	Expert International Clinical Reviewer for the Irish NCCP, Evidence-Based Guidelines on Diagnosis and Staging of Patients with Ovarian Cancer.
2017-2022	Member, Gynaecology Clinical Study Group, National Cancer Research Institute (NCRI), UK.
2017	Treasurer, Memorial Hospital Alumni Society Executive Council, MSKCC, New York, NY, USA.
2016-2022	Chair, Scientific Committee, ICIS.
2016-2019	Member, Board of Trustees, ISMRM.
2016-2017	Vice-Chair, SMRT Committee, ISMRM.
2015-present	Member, Board of Trustees, ICIS.
2015-2020	Chair, Oncologic Imaging Refresher Course Committee, RSNA.
2015-2017	Member, Memorial Hospital Alumni Society Executive Council, MSKCC, New York, NY, USA. ECOG-ACRIN Genitourinary Committee, American College of Radiology Imaging Network (ACRIN).
2014-present	Member, Meeting Program Committee, ICIS.
2014-2017	Advisor, Scholar Program, RSNA. Co-Chair, Uterine and Ovarian Cancer Disease-Focused Panel, SAR.
2014-2015	Chair, Uterine and Ovarian Cancer Disease-Focused Panel, SAR.

	Vice-Chair, Oncologic Imaging Refresher Course Committee, RSNA. Member, Nominating Committee, ISMRM.
2013-2017	Chief, Body Imaging Service, MSKCC, New York, NY, USA. Member, Radiology Faculty Excellence Committee, MSKCC, New York, NY, USA. Member, Anti-Angiogenic Agent based Radiosensitization working group, MSKCC, New York, NY, USA.
2012-2015	Director, Gynaecologic Radiology, MSKCC, New York, NY, USA.
2013-2014	Member, Genitourinary Scientific Subcommittee, ESR.
2012-2017	Member, Radiology Research Steering Committee, MSKCC, New York, NY, USA. Member, Radiology Department Recruitment Committee, MSKCC, New York, NY, USA.
2012-2014	Member, Radiology Faculty Retreat Committee, MSKCC, New York, NY, USA.
2011-2017	Member, Oncologic Imaging and Therapies Task Force, RSNA.
2011-2012	Member, Quality Standard for Ovarian Cancer Topic Expert Group, National Institute of Clinical Excellence, UK.
2010-2014	Member, Gynecology Committee, ACRIN.
2009-2022	Member, Advisory Panel, National Institute of Health Research, Health Technology Assessment Program.
2009-2012	Member, Imaging Group, European Organization for Research and Treatment of Cancer (EORTC). Member, Annual Meeting Program Committee, ISMRM.
2008-2012	Member, Faculty Board of Clinical Medicine, University of Cambridge, UK. Member, PET/CT Research Management Committee, Addenbrookes Hospital, Cambridge, UK. Member, Experimental Cancer Medicine Centre, Imaging Management Committee University of Cambridge, UK.
2007-present	Member, ESUR Female Pelvis Subcommittee. Member, Advisory Board Women's Imaging E-Community, American Roentgen Ray Society (ARRS).
2007-2013	Member, Radiographics Women's Imaging Panel, RSNA.
2006-2012	Member, Gynaecology Clinical Study Group, NCRI, UK. Member, Scientific Committee (Genitourinary), RSNA.
2005-2012	Imaging Lead for Gynaecology Oncology, East Anglia Cancer Network, UK.
2005-2012	Lead Consultant for Gynaecology Imaging and Imaging Lead, Gynaecology Oncology MDT, Addenbrookes Hospital, UK.

RESEARCH SUPPORT

2018-present

2025-2030	Quantum-enhanced and AI-powered metabolic MRI Diagnostics (Q-AID). DIGITAL-2024-AI-06. ID 101195272. Role: PI . Size: €8,296,221
2024-2029	THERA4CARE (IHI): Radiotheranostic solutions for solid tumour personalised treatment. ID 101172788. Role: Coordinator. Size: €25.329.093. UMBRELLA – GA n. 101172825 – IHI JU 5: Unleashing a CoMprehensive, Holistic and Patient Centric Stroke Management for a Better, Rapid, AdvancEd and Personalised Stroke Diagnosis, TreAtment and Outcome Prediction. Role: Partner. Size: €493.800.
2024-2026	PNRR-MCNT2-2023-12378360 “Radiogenomics to support and implement biomarkers guided delivery of precision medicine in uterine confined Endometrial Cancer”, CUP C53C23001200007; Role: Co-PI, PI Francesco Fanfani. Size €487.860.
2023-2028	EUropean Federation for CAncer IMages (EUCAIM) – GA n. 1011100633 – H2020. Role: Partner. Size: €265.574,00.
2023-2027	TRUSTroke – GA n. 101080564 – hlth-2022: Trustworthy Ai For Improvement of Stroke Outcomes. Role: Partner. Size: €6.076.437,50.
2022-2025	2022-2025 European Federation for Cancer Images (EUCAIM): DIGITAL-2022-CLOUD-AI-02 (CNECT), ID 101100633; Role: Co-I; PI Luca Boldrini. Size €265.714.
2021-2024	RE-SAMPLE – GA n. 965315 – H2020: Proactive and tailor-made care for complex chronic conditions. Role: Partner. Size: €690.625.
2021-2023	IHELP: Personalised Health Monitoring and Decision Support Based on Artificial Intelligence and Holistic Health Records – GA n. 101017441 – H2020. Role: Partner. Size: €482.222.
2021-2022	UKRI-EPSRC: Revolutionizing medical imaging (Relmagine) through ubiquitous, low-dose, automated computed tomography diagnostic systems. Role: Co-I, PI: Samuel Stranks. Size: £302,379.00.
2020-2025	oncNGS – GA n. 874467 – H2020. Role: Affiliated Entity. Size: €26.730.
2020-2023	TERMINET: nexT gEneRation sMart INterconnectEd IoT – GA n. 957406 – H2020. Role: Partner. Size: €103.125. CRUK ACED: LIMIT PCa (Luminal index MRI identification of treatment critical prostate cancer). Role: Co-I, PI: Shonit Punwani. Size: £583.560,17. H2020: CCE-DART (Building Data Rich Clinical Trials). Role: Co-I, PI: Elena Garralda (European consortium with Cambridge Co-PI). Size: €5.999.411,30.

H2020-IMI: DRAGON (Rapid and secure AI imaging-based diagnosis, stratification, follow-up, and preparedness for coronavirus pandemics). Role: Co-I, PI: Carola Schönlieb (European consortium with Cambridge PI). Size: €11.400.000.

EPSRC: EPSRC Hub Cambridge Mathematics of Information in Healthcare, Role: Co-I, PI: Carola Schoenlieb. Size: £1.300.000.

Armstrong Foundation: PhD funding for project: Unravelling tumour spatial and temporal heterogeneity using ultrasound analysis of the tumour microenvironment. Role: PI: Evis Sala. Size: £74.000.

2020-2022

Wellcome Trust Innovator Award: All in one cancer imaging optimisation using an integrated mathematical and deep learning approach. Role: PI: Evis Sala. Size: £714.682.

2019-2023

Horizon 2020 Framework Programme: Innovative medicines initiative: specific imaging of immune cell dynamics using novel tracer strategies. Role: Co-I, PI: Bert Windhorst. Size: €15.000.000.

CRUK Accelerator Award: National Cancer Imaging Translational Accelerator (NCITA). Role: Co-PI, PI: Shonit Punwani. Size: £10.000.000.

2019-2021

Target Ovarian Cancer: Unravelling the tumour immune microenvironment for new ovarian cancer treatment strategies. Role: Co-I, PI: Martin Miller. Size: £199.546.

2018-2021

The Mark Foundation for Cancer Research: The Mark Foundation Institute for Integrated Cancer Medicine (MI2CM). Role: Co-PI, PI: Richard Gilbertson. Size £8.600.000 (£4.400.000 for imaging)

2002-2017

2016-2018

Society of Abdominal Radiology Wylie J. Dodds Research Award: Stability of radiomic features for abdominal tumors on contrast enhanced CT with variable acquisition parameters. Role: Co-PI, PI: Kihn Gian Do, Size: \$15.000.

2016-2017

MSKCC, Experimental Therapeutics Center: Multi-modality treatment of pancreatic ductal adenocarcinoma (PDAC). Role: Collaborator, PI: Jason Lewis. Size: \$ 1,250,000.

2015-2016

MSKCC Radiology Developmental Project Seed Grant: Pilot Study: Rapid ovarian screening with MR Imaging in BRCA mutation carriers undergoing screening breast MRI. Role: Mentor, PIs: Yulia Lakhman, Lorenzo Mannelli & Elisabeth Sutton. Size: \$29.958.

2014-2017

Cancer Research UK: Development of hyperpolarized carbon-13 MRI as a novel clinical imaging tool in oncology, Role: Collaborator, PI: Ferdia Gallagher. Size: £1.400.000.

2014-2016

MSKCC Society Research Grant: Diffusion weighted Imaging as a biomarker for early detection of chemotherapy induced cardiotoxicity. Role: Co-PI, PI: Andrew Plodkowski. Size: \$98.937

Imaging and Radiation Sciences Program: Detection of acid sphingomyelinase/ceramide pathway activation in radiotherapy

	patients using intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging and serum biomarkers. Role: Co-PI, PI: Hebert Vargas. <i>Size: \$98.256.</i>
2014	RSNA R&E Foundation Research Medical Student Grant: Establishing tumor heterogeneity in patients with metastatic high-grade serous ovarian cancer (HGSOC): correlating in vivo imaging phenotypes with histopathology and immunohistochemistry. Role: Mentor, PI: Edward Lawrence. <i>Size: \$3.000.</i>
2013-2017	MSKCC Molecularly Targeted Intra-Operative Imaging RFA: Positron lymphography (PLG) sentinel lymph node mapping using PET/MR fusion imaging to guide and improve intraoperative nodal resection, Role: Co-PI, PI: Nadeem Abu-Rustum. <i>Size: \$32.899.</i> NHI-CIP TCIA-TCGA Multicentre Study in Ovarian Cancer Radiogenomics: Radiogenomics in ovarian cancer: linking imaging phenotypes with genomics. role: PI: Evis Sala. <i>Size: In kind.</i>
2013-2016	Kaleidoscope of Hope Foundation: Benchmarking intra-tumor heterogeneity in high grade serous ovarian cancer (HGSOC): linking in-vivo imaging phenotypes with histology and genomics. Role: Mentor, PI: Hebert Vargas & Britta Weigelt. <i>Size: \$80.000.</i> MSKCC Radiology Developmental Project Seed Grant: Benchmarking intra-tumor heterogeneity in ovarian cancer: linking in-vivo imaging phenotypes with genomics. Role: Mentor, PI: Hebert Vargas. <i>Size: \$96.537.</i>
2013-2014	MSKCC Radiology Developmental Project Seed Grant: Multi parametric imaging and genomics: can we predict clinical outcome in patients with recurrent cervical cancer undergoing pelvic exenteration. Role: Mentor, PI: Barbara Raphael. <i>Size: \$76.483.</i>
2011-2013	Cancer Research UK: Diagnostic accuracy of MRI, diffusion-weighted MRI, FDG-PET/CT and fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma. Role: Co-I, PI: Andrea Rockall, <i>Size: £225.698.</i>
2011-2012	Cancer Research UK: Standardization of DWI MRI for quantitative assessment of ovarian cancer and implementation in clinical trials. Role: Co-I, PI: Nandita DeSouza, <i>Size: £290.085.</i>
2010-2011	Sanofi-Aventis: Neoadjuvant docetaxel prior to radical prostatectomy for high risk localized prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy. Role: Co-I, PI: Danish Mazhar. <i>Size: £69.000.</i>
2009-2010	Merck & Co., Inc: A Multicenter trial to measure early patterns of change in [18F]-fluorodeoxyglucose uptake by PET/CT in relapsed ovarian cancer patients. Role: Co-PI. PI: Brenton, James. <i>Size: £589.284.</i>
2008-2009	Cancer Research UK (Cambridge Experimental Cancer Medicine Centre): The role of in vivo molecular and functional magnetic resonance imaging parameters in predicting response and

	resistance to androgen deprivation therapy in patients with prostate cancer. Role: Co-PI, PI: Vincent Gnanapragasam. <i>Size: £24.000.</i>
2007-2012	Cancer Research UK: Cambridge Experimental Cancer Medicine Centre. Role: Co-PI, Carlos Caldas. <i>Size: £2.000.000.</i>
2006-2009	Cancer Research UK: Profiling signatures of chemotherapy response or resistance in ovarian cancer: Correlation with dynamic magnetic resonance perfusion imaging. Role: PI: Evis Sala. <i>Size: £20.000.</i>
2004-2005	Addenbrooke's Charities: Evaluation of early abdomino-pelvic computed tomography in patients presenting with acute abdominal pain. Role: PI: Evis Sala, <i>Size: £8.950.</i>
2002-2005	Royal College of Radiologists: Breast density, breast cancer genetic markers and plasma sex steroid levels. Role: PI: Evis Sala. <i>Size: £8.000.</i>

Grant Reviewer

2025-present	Ermenegildo Zegna Founder's Scholarship, ITA.
2025-present	DKTK Joint Funding Call 2025, DEU.
2020-present	L'Oréal-UNESCO UKI for Women in Science Rising Talents Programme. Cancer Research UK. Wellcome Trust, UK. EPSRC, UK.
2017	Research Council, University of Leuven, BG. Target Ovarian Cancer, UK.
2016-present	National Cancer Institute's Clinical Imaging Program, USA.
2016	Worldwide Cancer Research. Wellcome Trust, UK. Cancer Research UK.
2010-present	Medical Research Council, Clinical Research Fellowships, UK.
2009	Courcher Foundation, Hong Kong.
2007-2022	Health Technology Assessment Program, National Institute of Health Research, UK.
2007	Prostate Cancer Charity, UK.

Keynote/Plenary Lectures

- Anatomia Radiologica della Pelvi. “La radiomica nell’imaging della pelvi”, December 14, 2024. Trento, Italy.
- Scientific symposium of the CD Laboratory Machine Learning Driven Precision Imaging, “Machine Learning in Cancer Imaging”. November 4th, 2024. Vienna, Austria. “Tumour heterogeneity - linking imaging with biology”.
- 2nd Rome Prostate Meeting. “Optimized Radiotherapy in Multimodality Therapy Era”. May 30, 2024, Rome, Italy.
- Roko Wiesbaden 2024. Radiologie in Transformation. “Highlight Lecture: Unravelling Tumour Heterogeneity in Ovarian Cancer Using a Radiogenomics Approach”. May 8-10, 2024, Wiesbaden.
- “La recidiva nei tumori ginecologici: nuove armi per un problema irrisolto”. Lectio Magistralis: “La recidiva da neoplasia ginecologica – evoluzione delle tecniche di imaging”. May 26th, 2023. Alberobello, Italy
- ISMRM Annual Meeting. The Lauterbur Lecture “Building Clinical Value in Cancer Care with Magnetic Resonance Imaging” May 7-12, 2022, London, UK.
- BIR Annual Congress. The BIR/Canon Mayneord Memorial Lecture “Integrated Radiogenomics for Virtual Biopsy and Treatment Monitoring in Ovarian Cancer”. November 4-6, 2020.
- World Molecular Imaging Congress Virtual 2020 Spotlight Lecture “Integrated Radiogenomics in Ovarian Cancer”. October 7 - 9, 2020.
- ESUR Honorary Lecture “Integrated Radiogenomics for Virtual Biopsy & Treatment Monitoring in Ovarian Cancer”. Society for Abdominal Radiology. March 1-6, 2020, Maui, HI, USA.
- AACR, Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Strategies. “Clinical challenges in oncological imaging: AI Support from Image Analysis to Integrated Diagnostics”. January 9-12, 2020, San Diego, CA, USA.
- 6th International Meeting on MRI in Oncology: New Frontiers. “Navigating Tumour Phenotype with Advanced MRI”. September 23-25, 2019, Novara, Italy.
- International Extracranial Germ Cell Tumour Conference. “Radiogenomics and Potential Applications to Germ Cell Tumours”. September 15-18, 2019, Cambridge, UK.
- 25th ESUR. “Advances in Oncologic Imaging: Ovary”. September 13-16, 2018, Barcelona, Spain.
- BIR Annual Meeting. “Unraveling Tumor Heterogeneity Using Next Generation Imaging: Radiomics, Radiogenomics and Habitat Imaging in Ovarian Cancer”. November 2-3, 2017, London, UK.
- 5th International Meeting on MRI in Oncology: Windows in Oncology MRI. “Oncological Imaging in the Era of Precision Medicine”. September 18-20, 2017, Novara, Italy.
- ESUR. “Imaging of Adnexal Masses: An Algorithmic Approach”. September 14-17, 2017, Sopot, Poland.
- British Gynecological Cancer Society Annual Meeting. June 15-16, 2017, Glasgow, UK.
 - “Unraveling Tumor Heterogeneity Using Next Generation Imaging: Radiomics, Radiogenomics and Habitat Imaging in Ovarian Cancer”
 - “Imaging in Early Cervical Cancer: The North American Approach”
- II International Multidisciplinary Medical Congress. September 15-17, 2016, Tirana, Albania.
 - “Oncological Imaging in the Era of Precision Medicine”
 - “Imaging of Gynecologic Tumors: Combining Morphology and Function”

- 75th Annual Meeting of the Japan Radiological Society. “Imaging of Gynecologic Tumors: Combining Morphology and Function”. April 14-17, 2016, Yokohama, Japan.
- Italian and Albanian School of Radiology Specialization Magistral Lecture 2015. “Ovarian Cancer: Imaging in Treatment Selection and Planning”. December 17, 2015, Italy.
- World Molecular Imaging Congress. September 2-5, 2015, Honolulu, HI, USA.
 - Women’s Imaging Spotlight session “Imaging of Gynecologic Tumors: Combining Morphology and Function”
 - Radiogenomics Spotlight session “Radiogenomics, the New Generation Imaging”
- Turkish Cancer Society Cancer Awareness Week: Advances in Oncology. “Oncogenetic intratumor variability translated to imaging: Radiomics and Radiogenomics”. April 4, 2015, Istanbul, Turkey.
- 16th International MRI Symposium. J. Doppman lecture: “MRI of the Cervix - Combining Morphology and Function.” January 29-31, 2015, Garmisch-Partenkirchen, Germany.
- The Korean Society of Urogenital Radiology (KSUR) Annual Meeting. April 26, 2014, Seoul, South Korea.
 - “Advances in Gynecology Oncology: Combining Morphology and Function”
 - “Staging Ovarian Cancer: What Technique is Best?”
- The Society for the Advancement of Women’s Imaging Annual Meeting. “Advances in Gynecologic Imaging”. October 18-21, 2012, Chicago, IL, USA.
- XI Annual Congress of the Spanish Abdominal Radiology Society (SEDIA). October 6-7, 2011, Ibiza, Spain.
 - “MRI of the Adnexa”
 - “Staging Ovarian Cancer”

Refresher Courses

- ECR, February 26 – March 2, 2025. Vienna, Austria.
 - “The hidden costs of Data Production and Storage in Radiology – An overview of the data tsunami in radiology”
 - “AI in Genitourinary Imaging – The challenges and opportunities for radiologists using AI in Genitourinary Imaging”
 - “AI-powered prostate cancer detection: a multi-centre, multi-scanner validation study”
 - “AI-SC 6 – Realizing the Quadruple Aim through AI: assessing economic, accessibility, quality and staffing dimensions”
- RSNA, December 1-5, 2024. Chicago, IL, USA. “Multiple centre external validation integrating clinical data with AI to optimise decision-making in prostate MRI”.
- 30th ESUR, September 19-22, 2024. Lisbon, Portugal.
 - “AI applications in gynaecological malignancies”
 - “Impact of AI on prostate MRI reporting for non-expert and expert readers in a multi-reader, multi-centre evaluation”
- ECR, February 28 – March 3, 2024. Vienna, Austria.
 - “Practical Applications of Radiomics: Ovarian Cancer”
 - “The impact of imaging in prostate cancer management: from tumour detection to theranostics”
 - “Assessing immunotherapy response with functional imaging and radiomics”
 - “The Future of Imaging”
 - “Impact of cloud and AI on Research and Clinical Imaging”
- ICIS, September 27-29, 2024. Singapore. “Multiomics Data Integration for Better Treatment Response Assessment and Prognostication”.

- RSNA, November 26-30, 2023. Chicago, IL, USA.
 - “A.I. driven tools and techniques in radiology education – Empowering the next generation of radiologists”
- ICIS 22nd Annual Teaching Course, September 25-27, 2023 London, UK. “Cancer Imaging: Current Guidelines for Best Practice”.
- TMC onsite course May 1-5, 2023 Barcelona
 - Female Pelvic Anatomy, MRI protocols and Reading Tips
 - MRI of uterine sarcomas
 - MRI of Endometrial Cancer
 - Ovarian Cancer Staging
 - Acute Pelvic Pain
 - Vulvar cancer imaging
- ECR, March 03-02, 2023 Vienna, Austria.
 - The impact of imaging on patient management: case-based gynaecological tumours: The importance of multidisciplinary committees and the growing role of the radiologist
 - Panel discussion on digital transformation in healthcare: Digital Transformation in Healthcare – A data-driven future
 - Ovarian cancer: Practical applications of radiomics
 - The gynaecology team: When the radiologist makes the difference
- RSNA, November 27 – December 1, 2022. Chicago, IL, USA.
 - “Ovarian Cancer: a glimpse into the future of personalized care”
 - “Generalisation of AI analysis for prostate cancer diagnostic imaging to multiple centres and scanners”
- ECR, July 13-17, 2022, Vienna, Austria.
 - “Radiomics Promises in Ovarian Cancer Management”
 - “AI and the integration of -omics biomarkers for the prediction of response to treatment”
 - “Making the most of opportunities: What I have learned”
 - “Ovarian cancer: a multidisciplinary approach: Multidisciplinary tumour board: case-based panel”
- European Society for Medical Oncology (ESMO) Annual Meeting. “AI for image analysis of cancer therapy response”. September 16-21, 2021.
- European Society for Therapeutic Radiology and Oncology (ESTRO) Annual Meeting. “Functional MRI for cervical cancer”. August 27-31, 2021, Madrid, Spain.
- International Society for Computational Biology 29th Conference on Intelligent Systems for Molecular Biology and the 20th European Conference on Computational Biology. “Integrated radiogenomic for unravelling tumour heterogeneity and treatment monitoring in ovarian cancer”, July 25-30, 2021.
- ISMRM Annual Meeting. “Tumour Heterogeneity in Ovarian and Kidney Cancers.” May 15-20, 2021.
- ECR, March 3-7, 2021.
 - “Linking radiomics features to other omics data in clinical practice”
 - “Functional MRI for cervical cancer”
 - “DWI of pelvic organs”
- ECR, Highlights Week Abdominal Gastrointestinal/Genitourinary. “DWI of Pelvic Organs”. October 15, 2020.
- The 105nd Scientific Assembly and Annual Meeting of the RSNA, November 30 - December 6, 2019, Chicago, IL, USA.
 - “Novel Discoveries Using the NCI's Cancer Imaging Archive (TCIA) Public Data Sets: Ovarian Cancer”

- “Imaging in Proteogenomics Research: Ovarian Cancer”
- ECR, February 27 – March 3, 2019, Vienna, Austria.
 - “Advanced Imaging Techniques in Metastatic Gynaecological Cancer”
 - “Navigating Tumour Phenotype with Advanced Imaging Analysis”
 - “Functional Imaging of Female Pelvis: Tumours of the Uterus”
 - “Imaging Heterogeneity and Genomic Variability in Ovarian Cancer”
- The 104nd Scientific Assembly and Annual Meeting of the RSNA, November 24 - 30, 2018, Chicago, IL, USA.
 - “Novel Discoveries Using the NCI's Cancer Imaging Archive (TCIA) Public Data Sets”: Ovarian Cancer
 - “Interrogating Tumour Heterogeneity Using Imaging”
- ECR, February 28 – March 4, 2018, Vienna, Austria.
 - “The Ten-Minute Abdominal MRI, Make the Dream Come True: Ovaries”
 - “Radiomics: Biological Correlation”
 - “Update on Functional Genitourinary MRI: Uterus”
 - “Imaging Heterogeneity and Genomic Variability in Ovarian Cancer”
- The 103rd Scientific Assembly and Annual Meeting of the RSNA, November 26 - December 1, 2017, Chicago, IL, USA.
 - “Abbreviated of the Uterus and Cervix: Where and Why?”
 - “Imaging Radiomics Genomics Proteomics Interactions - New Frontiers Ahead”
 - “The Cancer Genome Atlas: the Role of Imaging in Interrogating Tumor Biology and Genomics in Ovarian Cancer”
 - “Keynote presentation: The added Value of MRI in Evaluation of Uterine Malignancies”
- ARRS Annual Meeting. “Imaging of Gynecologic Malignancies.” April 30 - May 5, 2017, New Orleans, IL, USA.
- ISMRM Annual Meeting, April 22-27, 2017, Honolulu, HI, USA.
 - “Body MRI: Optimize Your Clinical Practice: Female pelvis - Uterus”
 - “Imaging Tumor Response to Therapy: GYN Therapy Response”
- ECR. “MRI for Gynecologic Imaging How I do it: Diffusion and ADC”, March 1-5, 2017, Vienna, Austria.
- The 102nd Scientific Assembly and Annual Meeting of the RSNA, November 27 - December 2, 2016, Chicago, IL, USA.
 - “Imaging Radiomics Genomics Proteomics Interactions - New Frontiers Ahead”
 - “Ovarian cancer: the role of imaging in interrogating tumor biology and genomics/proteomics”
- ECR, March 2-6, 2016, Vienna, Austria.
 - “Pitfalls in gynaecologic oncologic imaging: how to avoid them and minimise risks”
 - “Imaging of Gynecologic Tumors: Combining Morphology with Diffusion and ADC”
- ISMRM Annual Meeting. “Adnexal Masses.” May 30-June 5, 2015, Toronto, Canada.
- The 100th Scientific Assembly and Annual Meeting of the RSNA. “Interactive game: A Case-based Audience Participation Session (Genitourinary) “. November 29 - December 5, 2014, Chicago, IL, USA.
- ISMRM Annual Meeting. “Adnexal Masses.” May 10-16, 2014, Milan, Italy.
- ECR. “Pitfalls in MRI of the Pelvis” March 6-10, 2014, Vienna, Austria.
- ISMRM Annual Meeting. “Cervical Carcinoma: Staging & Follow-Up”. April 20-26, 2013 Salt Lake City, UT, USA.
- The 99th Scientific Assembly and Annual Meeting of the RSNA. “Interactive game: A Case-based Audience Participation Session (Genitourinary) “. December 1-6, 2013, Chicago, IL, USA.

- ECR, March 7-11, 2013, Vienna, Austria.
 - “The Female Pelvis: An interactive case discussion”
 - “Pitfalls in MRI of the Pelvis”
- The 98th Scientific Assembly and Annual Meeting of the RSNA. November 25-30, 2012, Chicago, IL, USA.
 - “MRI of the Adnexa: the Essentials and Beyond”
 - “GU Diagnosis Live - A Case-based Audience Participation Session”
- ISMRM Annual Meeting. May 7-13, 2012, Melbourne, Australia.
 - “Uterus: Gauging Depth of Invasion”
 - “Anatomy and Staging of Vulva Cancer: All you Need to Know”
- ECR. “The Acute Female Pelvis” March 1-6, 2012, Vienna, Austria.
- The 97th Scientific Assembly and Annual Meeting of the RSNA. “MRI of the Adnexa: The Essentials and Beyond”. November 26-December 2, 2011, Chicago, IL, USA.
- ISMRM. May 7-13, 2011 Montreal, Canada.
 - “Malignant Uterine Abnormalities”
 - “MRI of the Ovarian Cancer: Staging, Treatment Response, and Detection of Recurrence”
- ECR. “Staging Ovarian Cancer: What Technique is the Best?” March 3-8, 2011, Vienna, Austria.
- The 96th Scientific Assembly and Annual Meeting of the RSNA. “The Added Value of Diffusion-Weighted and Dynamic Multiphase Contrast-enhanced MR Imaging of Gynecologic Malignancies.” November 27-December 3, 2010, Chicago, IL, USA.
- ISMRM Annual Meeting. “Ovarian Masses.” May 1-7, 2010, Stockholm, Sweden.
- The 95th Scientific Assembly and Annual Meeting of the RSNA. “The Added Value of Functional MR Imaging in the Evaluation of Gynecologic Malignancies. November 28-December 4, 2009, Chicago, IL, USA.
- ECR. “Normal Anatomy (US, CT PET/CT and MRI).” March 9-13, 2008, Vienna, Austria.
- ECR. “Benign Tumors of the Uterus: Detection and Characterization.” March 9-13, 2007, Vienna, Austria.
- ISMRM Annual Meeting. “Uterine malignancies.” May 19-25, 2007, Berlin, Germany.
- ARRS Annual Meeting. “MRI of Malignant Neoplasms of Uterine Corpus and Cervix.” April 30-May 5, 2006, Vancouver, Canada.

Invited Lectures

- ESUR Female Pelvis Imaging Course. “Follow-up in patients with ovarian cancer”. April 11-13, 2025. Rome, Italy.
- Body MRI nell'era dell'AI: protocolli ottimizzati e interpretazioni delle immagini. “AI applications in female pelvis imaging”. February 14, 2025. Milan, Italy.
- 51° Congresso Nazionale SIRM “THE NEXT GENERATION”. “Imaging quantitativo della pelvi femminile”. June 21, 2024. Milan, Italy.
- L'isola della diagnostica: Evoluzione tecnologica e Intelligenza Artificiale in Diagnostica per Immagini. Stato dell'arte e Prospettive. “I.A. nella gestione del flusso di lavoro”. November 11, 2024. Rome, Italy.
- Erasmus Course on Magnetic Resonance Imaging – Abdominal and Urogenital MRI. October 31-November 3, 2024. Palermo, Italy.

- “Benign uterus”
 - “Malignant uterus”
- 23rd Annual Teaching Course of the ICIS Joint Meeting with SGCR-WIRES. “Multiomics data integration for better treatment response assessment and prognostication”. September 27th-29th, 2024. Singapore.
- ESOR Visiting Professorship Programme to Ukraine. Online Meeting, May 16, 2024.
 - “PET-MR” in gynecological oncology”
 - “Artificial Intelligence in pelvis Oncology”
- The 83rd Annual Meeting of the Japan Radiological Society (JRC). Leading an Era of Transformation. April 11-14, 2024 Yokohama, Japan.
 - “Unravelling Tumour Heterogeneity in Ovarian Cancer using a Radiogenomics approach”;
 - “Next Generation Imaging of Renal Cell Carcinoma”
- 10 Symposium MR in RT. “Building clinical value with MRI in cancer care”, April 3-5, 2024 Rome, Italy.
- ESGO 2024. Workshop 6: How to read and interpret radiologic imaging in gynaecological cancers. “Imaging of Uterine Malignancies- The Radiologist’s perspective”. March 7-10, 2024 Barcellona, Spain.
- 10° Simposio Annuale di Radioterapia UPMC Hillman Cancer Center. La moderna integrazione tra la diagnostica e la terapia: il peso dell’innovazione tecnologica. “Radiogenomica integrate per una terapia di precisione”. December 15, 2023, Rome, Italy.
- SIRM, Annual Conference of Sub-specialty Sections. CARVAT is back New technologies in Diagnostic and Interventional Radiology. Magnetic Resonance Session, “Next Generation imaging of ovarian masses”. October 19-21, 2023, Rome, Italy.
- Journées Francophones de Radiologie (JFR). “Radiomics in Ovarian Cancer”. October 13-16, 2023. Paris, France.
- 33rd Residential Course, Modern Radiation Oncology. Innovation in personalized oncology: back to the future. “Quantitative imaging for Radiation oncologists”. October 9-11, 2023, Rome, Italy.
- ESOI Touchdown Meeting. “Radiomics for treatment assessment”. September 7-9, 2023, Pisa Italy.
- 3rd multidisciplinary meeting on Artificial Intelligence and Machine Learning in Cancer Imaging 3.0. Enhancing Healthcare through AI. Lecture “Getting the AI tool working in the clinical workflow”, June 30-July 1, 2023, Lisbon, Portugal.
- “La Recidiva nei Tumori ginecologici: nuove armi per un problema irrisolto. Lectio Magistralis “La recidiva da neoplasia ginecologica. Evoluzione delle tecniche di Imaging”, May 26, 2023, Alberobello (BA), Italy.
- BioMedical Engineering and Imaging Institute. BMEEI Symposium, New York Academy of Medicine. “Building Clinical Value in Cancer Care with MRI” April 20-21, 2023, New York, USA.
- EANM Focus 5, the international conference on “Molecular Imaging and Theranostics in Prostate Cancer - the future begins today” Staging Prostate Cancer: The Evolving Role of Radiology February 02 - 04, 2023, Seville, Spain.
- 23rd Total Radiology Conference Arab Health “The future of genitourinary imaging” January 30 – February 02, 2023, Dubai, UAE.
- International Digital Symposium, online webinar. “New Horizons in the Therapy of Gynecologic Cancer”. November 7-14-21, 2022, Italy.

- Medical Image Analysis and Artificial Intelligence Symposium Keynote Lecture “Integrated Radiogenomics for Unravelling Tumour Heterogeneity and Treatment Monitoring in Ovarian Cancer”. September 22, 2022, Krems, Austria.
- 32nd Residential Course, Modern Radiation Oncology: multidisciplinary in the era of OMICS and AI guided oncology. “Radiomics: methods and general applications”. September 17-19, 2022, Rome, Italy.
- Moderna Radioterapia Oncologica: Approcci multidisciplinari nell’era dei trattamenti guidati dalle Omiche a dall’Intelligenza Artificiale. Lectio Magistralis: “Radiomica e Intelligenza Artificiale nella radiodiagnostica delle neoplasie mammarie e ginecologiche”. September 16, 2022, Campobasso, Italy.
- BGCS Annual Scientific Meeting. “Integrated Radiogenomic for Unravelling Tumour Heterogeneity and Treatment Monitoring in Ovarian Cancer”. July 7-8, 2022, London, UK.
- EMRI Erasmus Course. “Cervix: imaging for treatment planning from staging to salvage therapy”. July 6-9, 2022, London, UK.
- The Virtual EANM Multidisciplinary Days. “AI & Radiomics for Advanced Imaging Analysis - What’s New?” June 28-30, 2022.
- Workshops at the 10th IDKD Intensive Course in Asia. May 27-29, 2022, Singapore.
 - “Renal, Adrenal and Prostate Tumours”
 - “Cancers of the Female Genital Tract”
- Campus per Specializzandi di Imaging Oncologico. “Oncologic Imaging: present and future. Building Clinical Value in Cancer Care with Magnetic Resonance Imaging”, May 2-4, 2022, Pisa, Italy.
- Scandinavian Computed Tomography Course. “CT for staging of ovarian cancer and peritoneal carcinomatosis”. April 27-29, 2022, Larvik, Norway.
- Visiting Professor Lectures at the University of Toronto, March 31, 2022.
 - “Update on Advanced MRI of Uterine Malignancies”
 - “Integrated Radiogenomic for Unravelling Tumour Heterogeneity and Treatment Monitoring in Ovarian Cancer”
- 14th Breast, Gynaecological and Immunooncology International Cancer Conference. January 20-21, 2022, Cairo, Egypt.
 - “Tips and tricks on gynecologic MRI protocol and reporting”
 - “Algorithmic approach to characterization of adnexal masses on MRI”
 - “MRI of uterine Malignancies”
 - “Artificial Intelligence for image analysis of pelvic cancer therapy response”
- Royal Society & Academy of Medical Sciences Symposium, Diagnostics: Building capacity and capability in the UK. “Integrated Radiogenomics for Unravelling Tumour Heterogeneity and Treatment Monitoring”. October 12, 2021, London, UK.
- ESGE 30th Annual Congress. “Integrated radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer”. October 3-5, 2021, Rome, Italy.
- The 19th Annual Teaching Course of the ICIS. “Staging of Uterine Malignancies and the Impact on Treatment Selection and Planning.” September 19-22, 2021.
- Cambridge Imaging Festival “Integrated Cancer Imaging with a focus on Ovarian and Renal Cancer”. May 25-26, 2021.

- British Society of Urogenital Radiology Virtual Cambridge Meeting “Radiogenomics in Gynaecological Cancer”. May 19-20, 2021.
- SIGNA™ Masters 2021 ISMRM Research Summit “C13 Applications in Oncology”. May 18, 2021.
- MaGIC Biology Webinar “Integrated Radiogenomic for Treatment Monitoring in High-grade Serious Ovarian Cancer” May 18, 2021.
- NCI APOLLO Imaging Working Group. “Ovarian Cancer Radiogenomics”. April 14, 2021.
- TMC Academy Webinar. “Algorithmic Approach to Characterization of Adnexal Masses on MRI”. April 8, 2021.
- Prostate Cancer Foundation Imaging webinar series. “Habitat Imaging for Unravelling Tumour Heterogeneity and Treatment Monitoring in Ovarian Cancer”. March 6, 2021.
- Stanford Cancer Institute, Frontiers in Oncology. “Integrated Radiogenomics for Treatment Monitoring in High-Grade Serous Ovarian Cancer.” February 2, 2021.
- ICIS Webinar on Abbreviated MRI Protocols in Cancer. “Abbreviated Gynaecological MRI Protocols”. January 12, 2021.
- MedTech NAVIGATOR Programme, The Future of Cancer Care. “Clinical Challenges in Diagnostic Radiology: AI Support from Workflow to Integrated Diagnostics”. November 19, 2020.
- ESOR Galen Course Urogenital Radiology. “Ovarian Cancer Staging”. October 2, 2020.
- New Horizons in Radiology. “Update on Advanced MRI of Uterine Malignancies”, September 18-19, 2020, Berlin, Germany.
- ESOR Galen Course MR Imaging of the Abdomen. “MR Imaging of the Ovaries”. September 4, 2020.
- ESR/ESOR Premium Event, AI in Oncologic Imaging. “AI Interpretation of Intratumoral Heterogeneity”. July 20-23, 2020.
- National Cancer Imaging Translational Accelerator Webinar: Optimizing Imaging in the ‘Omics’ Era. “Integrated Radiogenomics for Virtual Biopsy and Treatment Monitoring in Ovarian Cancer”. June 12, 2020.
- SMRT/ISMRM MR of Cancer study group virtual meeting. “Habitat Imaging with a Particular Emphasis on Validation of MRI Biomarkers for Imaging Tumor Heterogeneity. June 11, 2020.
- Borysiewicz Fellows' Virtual Leadership Event: Accessing and Managing Research Funds Workshop. “Insights from a reviewer”. University of Cambridge, UK June 1, 2020.
- Philips 2nd annual AI conference (OCUPAI'20). “Clinical Challenges in Diagnostic Radiology: AI Support from Workflow to Integrated Diagnostics”. May 19, 2020.
- ESUR Course Topics in Female Pelvic Imaging. “New Perspectives: Imaging Biomarkers, Quantitative Imaging Radiomics and Radiogenomics”. February 6-8, 2020, Rome, Italy.
- 12th Teaching Course on Advances in Pelvic Imaging, January 30-31, 2020, Madrid, Spain.
 - “MRI of the Malignant Endometrial Tumours”
 - “MRI of Cervical Cancer”
 - “Ovarian Cancer: Role of Imaging in Treatment Selection and Planning”
 - “Radiomics of Ovarian Cancer”
- The RCR Clinical Radiology Research Day, November 20, 2019, London, UK.
 - “Life as an Academic Radiologist”

- “Clinical Challenges for AI in Oncological Imaging”
- 40th TURKRAD Annual Congress of Radiology, November 5-10, 2019, Antalya, Turkey.
 - “Clinical Challenges in Oncological Imaging: AI Support from Workflow to Integrated Diagnostics”
 - “Whole Body Metastatic Disease”
 - “Interrogating Tumour Heterogeneity Using Imaging: The Role of Radiomics/Radiogenomics”
- Artificial Intelligence Developments in Healthcare Imaging. “Clinical Challenges for AI in Oncological Imaging”. Isaac Newton Institute, October 23-24, 2019, Cambridge, UK.
- The Royal College of Radiologists RCR19 Annual Conference. “Radiogenomics”. October 14-16, 2019, Liverpool, UK.
- The 19th Annual Teaching Course of the International Cancer Imaging Society. October 7-9, 2019, Verona, Italy.
 - “Clinical Challenges in Diagnostic Radiology: from Workflow to Integrated Diagnostics”
 - “Ovarian Cancer: Role of Imaging in Treatment”
- 6th International Meeting on MRI in Oncology: New Frontiers. “Abbreviated MRI in GYN: Where and When?”, September 23-25, 2019, Novara, Italy.
- 26th European Symposium on Urogenital Radiology. “Radiomic Approaches in Ovarian Cancer”, September 19-22, 2019, Dublin, Ireland.
- 11th International Workshop on Pharmacodynamics of Anticancer Agents. “Imaging and Clinical Outcomes”. September 8-12, 2019, Monestier, France.
- Royal Marsden Imaging Perspectives: RECIST 1.1 and beyond; A new era for tumour response assessments. “Evolution of Imaging Cancer Response: Meeting the Needs of Modern Oncology”. June 21, 2019, London, UK.
- 106th Swiss Congress of Radiology. “Uterine Pathologies: Correlation Between Histology and Imaging Features”. June 13-15, 2019, St Gallen, Switzerland.
- 100th German Radiology Congress, May 29 – June 1, 2019, Leipzig, Germany.
 - “Cancer Staging: How to Image and Report Female Pelvis”
 - “Radiogenomics Live: Practical Application in Ovarian Cancer”
- The Wizardry of Artificial Intelligence: AI and Machine Learning in Cancer Imaging. “Clinical Challenges in Diagnostic Radiology: From Workflow to Integrated Diagnostics”. May 17-17, 2019, Lisbon, Portugal.
- 11th Breast, Gynaecology and Immunooncological International Cancer Conference. January 17-18, 2019, Cairo, Egypt.
 - “MRI in Uterine Malignancies”
 - “Algorithmic Approach to Characterisation of Ovarian Masses on MRI”
 - “Imaging of the Treated Pelvis”
 - “Pitfalls in MRI of Female Pelvis”
- ESOR/Champalimaud Foundation Symposium on Imaging Hallmarks of Cancer. “Radiomics: Biological Correlation and Clinical challenges”. October 18-19, 2018, Lisbon, Portugal.
- ICIS Meeting and 18th Annual Teaching Course. October 7-9, 2018, Menton, France.
 - “Gynaecological Cancer Hands-on Workshop”
 - “Cases I would Like to Read Again: Female Pelvis”
- Ontario Association of Radiologists 2nd Abdominal and Pelvic Oncology Imaging CME Event. September 22, 2018, Toronto, Canada.
 - “Interactive Workshop 1: Algorithmic Approach to Female Pelvic Mass”

- “Ovarian Cancer: Role of imaging in Treatment Selection”
 - “Imaging of the Treated Pelvis”
- ESMRMB School of MRI Advanced Pelvic MR Imaging. “Malignant Diseases of Uterus.” September 6-8, 2018, Rome, Italy.
- ESOR Visiting Professorship Programme & Armenian Congress of Radiology Abdominal Oncologic Imaging. June 29-30, 2018, Yerevan, Armenia.
 - “Ovarian Cancer: Role of Imaging In Treatment Selection and Planning”
 - “Prostate Cancer Imaging and MRI Protocol Optimisation”
 - “Update on Functional Genitourinary MRI: Uterus”
- ESOR ASKLEPOIS Course on Women’s Imaging, “PET MRI in Gynaecological Oncology”. May 11-12, 2018, Bucharest, Romania.
- Visiting Professor Lecture at Stanford University, “Unraveling Tumor Heterogeneity Using Next Generation Imaging: Radiomics, Radiogenomics and Habitat Imaging In Ovarian Cancer.” May 1, 2018, Palo Alto, CA, USA.
- East Anglian Radiology Society Annual Meeting. “Unravelling Tumour Heterogeneity in Ovarian Cancer: Radiomics, Radiogenomics and Habitat Imaging” March 21, 2018, Cambridge, UK.
- Oman Radiology and Molecular Imaging Society Annual Meeting. February 2-3, 2018, Muscat, Oman.
 - “Imaging, Staging of Endometrial Cancers”
 - “Cervical Cancer Imaging”
 - “Algorithmic Approach to Characterization of Adnexal Masses Using MRI”
 - “Ovarian Cancer: Diagnosis and Staging”
 - “Imaging of the Treated Pelvis: Pearls and Pitfalls”
- 3rd RSSA-ICIS Satellite Cancer Imaging Course. January 19-21, 2018, Stellenbosch, South Africa.
 - “Female Pelvis”
 - “Whole Body Imaging of Metastatic Disease”
 - “Female Pelvis Workshop”
 - “Whole Body Imaging of Metastatic Disease Workshop”
- National Diagnostic Imaging Symposium 2017. December 4-6, 2017, Hollywood, FL, USA
 - “Imaging of the Acute Female Pelvis”
 - “An Algorithmic Approach to Female Pelvic Masses”
 - “Ovarian Cancer: Imaging in Treatment Selection and Planning”
- Intensive Pelvic MRI Course. October 26-29, 2017, Melbourne, Australia.
 - “MRI of the Prostate: What is the Best Protocol”
 - “MR Imaging of the Treated Prostate: Pearls and Pitfalls
 - “Gynecologic MRI Acquisition Protocols and Reporting Guidelines”
 - “The Role of MRI in the Management of Uterine Malignancies”
 - “A Logarithmic Approach to MRI Characterization of Adnexal Lesions”
- International Cancer Imaging Society Meeting and 17th Annual Teaching Course. October 2-4, 2017, Berlin, Germany.
 - “Ovarian Cancer: Role of Imaging in Interrogating Tumour Biology and Genomics”
 - “Uterine Cancers Hands-on Workshop”
 - “Understanding Female Pelvis Spread patterns: Can Imaging Provide a GPS for Treatment Planning and Surgical Guidance in Ovarian cancer?”
- Imaging of the Abdomen Bottom to Top. September 21 - 22, 2017, Treviso, Italy.
 - “An Algorithmic Approach to Characterize Adnexal Lesions”
 - “The Role of MRI in the Management of Uterine Malignancies”

- “Imaging as a GPS for Staging Ovarian Cancer”
 - “Case Review Female Pelvis”
- Mount Sinai Medical Center TMI Frontier of Imaging Seminar Series “Unraveling Tumor Heterogeneity Using Next Generation Imaging: Radiomics, Radiogenomics and Habitat Imaging.” May 24, 2017, New York, NY, USA.
- ESOI 2017 Webinar 5 “Imaging of the Treated Pelvis: Pearls and Pitfalls.” May 24, 2017.
- Society of Abdominal Radiology Annual Scientific Meeting and Educational Course. March 26 - 31, 2017, Hollywood, FL, USA.
 - “Endometrial and Cervical Cancer: How MRI Guides Management”
 - “Advanced Female Pelvic MRI Hands-on Workshop”
- 17th International MRI Symposium. February 1-3, 2017, Garmisch-Partenkirchen, Germany.
 - “Fertility Clinic: Role of Radiology”
 - “MRI of the Prostate: What is the Best Protocol?”
- Practical Management Strategies and New Innovations in Prostate Radiotherapy “Multi-parametric MRI: Opportunities to Assess and Predict Treatment Response.” December 8-9, 2016, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Pelvic MRI Course (Course Director). November 12-14, 2016, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
 - “Gynecologic MRI Acquisition Protocol and Normal Anatomy as Visualized on MRI”
 - “Added role of MRI in treatment stratification and post-treatment follow-up of endometrial and cervical cancers”
 - “Pain in the Treated Pelvis: Imaging Recurrent Gynecologic Cancers”
- State of the Art Ovarian Cancer Conference “Precision Imaging: CT Scan and Protocol Enhancement.” October 6, 2016, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Oncologic Imaging Course: Current Practice and Future Trends in Oncologic Imaging. June 30- July 2, 2016, Dubrovnik, Croatia.
 - “Algorithmic Approach to the Female Pelvic Mass”
 - “Imaging of the Treated Pelvis: Pearls and Pitfalls”
- Visiting Professor Lecture at MD Anderson Cancer Center, “Oncogenetic Intratumor Variability Translated to Imaging: Radiomics and Radiogenomics for Assisting Diagnosis and Predicting Outcome in Genitourinary Malignancies.” June 15-17, 2016 Houston, TX, USA.
- Abdominal & Pelvic MRI 2016: Imaging Review of GI and GU Tracts. Harvard Medical School. June 6-8, 2016, Boston, MA, USA.
 - “MRI Techniques in the Pelvis: How and Why We Do It?”
 - “MRI Uterine & Cervical Cancer”
 - “MRI of The Adnexae”
 - “Case-Based Interactive Session - Female Pelvis”
- 46th Sao Paulo Radiology Meeting. April 28 – May 1, 2016, San Paolo, Brazil.
 - “Imaging of Gynaecologic Tumors: Combining Morphology and Function”
 - “Oncogenetic Intratumor Variability Translated to Imaging: Radiomics and Radiogenomics”
 - “Imaging In Cervical Cancer: Detection, Staging and Follow-Up”
 - “MRI of The Adnexa: The Essentials and Beyond”
 - “Post-Treatment Imaging of Gynecologic Malignancies: Case-Based Review”
 - “Radiomics: Imaging the Genes”
- ECR, E³ - European Diploma Prep Sessions. “Disorders of the Adnexa” March 2-6, 2016, Vienna, Austria.

- Visiting Professor Lecture at the Department of Radiology, University of Kyoto, Japan. March 14-18, 2015, Kyoto, Japan.
 - "Imaging of Gynecologic Tumors: Combining Morphology and Function"
 - "Oncogenetic Intratumor Variability Translated to Imaging: Radiomics and Radiogenomics for Assisting Diagnosis and Predicting Outcome in Genitourinary Malignancies"
- Intensive Pelvic MRI Course. February 19-21, 2015, Melbourne, Australia.
 - "Prostate Cancer Imaging & MRI Protocol Optimization"
 - "Risk-Adapted Prostate Imaging"
 - "MRI of GYN Malignancies"
 - "A Logarithmic Approach to MRI Characterization of Adnexal Lesions"
 - "MRI of Bladder and Vulvar Cancer, What You Need to Know"
- Visiting Professor Lecture at the Department of Radiology, Baptist Hospital, Miami, Florida. "Imaging of Gynaecologic Tumors: Combining Morphology and Function" January 11, 2016, Miami, FL, USA.
- Genetics and Genomics of Gynecologic Cancers Course. October 15-16, 2015, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
 - "Ovarian Cancer: The Role of Imaging in Interrogating Tumor Biology and Genomics"
 - "Imaging of Endometrial Cancer: Combining Morphology and Function"
- Visiting Professor Lecture at the Department of Radiology, University of Cambridge. "Oncogenetic Tumor Heterogeneity Translated to Imaging: Radiomics and Radiogenomics" October 7, 2015, Cambridge, UK.
- International Cancer Imaging Society Meeting and 15th Annual Teaching Course. Hands-on workshop: "Adnexal Masses and Ovarian Cancer." October 5-7, 2015, London, UK.
- World Molecular Imaging Congress. "Oncogenetic Intratumor Variability Translated to Imaging: Radiomics and Radiogenomics" September 2-5, 2015, Honolulu, HI, USA.
- Oncologic Imaging Course: Current Practice and Future Trends in Oncologic Imaging. June 25-27, 2015, Dubrovnik, Croatia.
 - "Differentiating Benign from Malignant Disease: How and When not to Sit on the Fence"
 - "How Does Imaging Direct Management in Patients With Uterine Malignancies?"
- Oncologic Imaging Course: The MSK Disease Management Team Approach. "Endometrial Cancer." May 14-16, 2015, New York, NY, USA.
- MSKCC Pelvic MRI Course (Course Director). April 27-29, 2015, New York, NY, USA.
 - "How I report a GYN MRI?"
 - "Differentiating Benign from Malignant Disease: How and When not to Sit on the Fence"
 - "Endometrial Cancer: What Is the Added Value of MRI?"
 - "Rare Gynecologic Cancers: Vulva/Vagina, Gestational Trophoblastic Disease"
- Visiting Professor Lecture at the Department of Radiology, Winthrop University Hospital. "MR Imaging of Adnexal Masses" May 8, 2015, New York, NY, USA.
- Barcelona Pelvic MRI Course. April 17-18, 2015, Barcelona, Spain.
 - "MRI of Ovarian Diseases: the Essentials and Beyond"
 - "Endometrial Cancer: The Added Value of MRI"
- Turkish Cancer Society Cancer Awareness Week: Advances in Oncology. "Assessment of Uterine Malignancies". April 4, 2015, Istanbul, Turkey.
- Society of Abdominal Radiology Annual Scientific Meeting and Educational Course. March 22 - 27, 2015, San Diego, CA, USA.
 - "MRI Female Pelvis Cases for Aces"

- "Imaging Treated Prostate Cancer"
- Intensive Pelvic MRI Course. January 20-22, 2015, Melbourne, Australia.
 - "GYN Malignancies Review, FIGO Staging and MRI Protocol Optimization"
 - "GYN Benign Disease Review, Indications for MRI Compared to US and CT"
 - "MRI of other GU Malignancies: Bladder and Vulvar cancer, What you Need to Know"
 - "Prostate Cancer Imaging & MRI Protocol Optimization"
- 16th International MRI Symposium. "MRI of the Adnexa – the Essentials and Beyond." January 29-31, 2015, Garmisch-Partenkirchen, Germany.
- New York Roentgen Society Meeting. "Ovarian Cancer: Role of Imaging in Treatment Selection and Patient Management". January 12, 2015, New York, NY, USA.
- Visiting Professor Lecture at the Department of Radiology, Columbia University. "MRI of the Adnexa – the Essentials and Beyond." December 19, 2014, New York, NY, USA.
- International Cancer Imaging Society Meeting and 14th Annual Teaching Course. Hands-on workshop: "Role of Imaging in Ovarian Mass: Imaging in Treatment Selection and Planning with FIGO Update." October 9-11, 2014, Heidelberg, Germany.
- 4th International Meeting on MRI in Oncology: The Evolution. "MRI after Therapy." September 24-26, 2014, Novara, Italy.
- The Society for the Advancement of Women's Imaging Annual Meeting. August 21-24, 2014, Chicago, IL, USA.
 - "MRI of the Adnexa: The Essentials and Beyond"
 - "Revised FIGO Staging of Uterine Malignancies: Implications for MRI"
 - "The Added Value of DWI in Gynecologic Oncology Imaging"
- Seoul National University Hospital. "MRI of the Adnexa: The Essentials and Beyond." April 25, 2014, Seoul, South Korea.
- Workshop at the 46th Davos International Diagnostic Course. "Adnexal Diseases." March 30-April 4, 2014, Davos, Switzerland.
- Society of Abdominal Radiology Annual Scientific Meeting and Educational Course. March 23 - 28, 2014, Boca Raton, FL, USA.
 - "Pitfalls in MRI of the Pelvis"
 - "Emerging Role of PET in Advanced Prostate Cancer"
 - "MRI Female Pelvis - Cases for Aces: a case-based review"
- Intensive Pelvic MRI Course. February 8-10, 2014, Melbourne, Australia.
 - "GYN Malignancies Review, FIGO Staging and MRI Protocol Optimization"
 - "GYN Benign Disease Review, Indications for MRI Compared to US and CT"
 - "MRI of Other GU Malignancies: Bladder and Vulvar Cancer, What You Need to Know"
 - "Prostate Cancer Imaging & MRI Protocol Optimization"
- Third Albanian Oncology Association Meeting: "Testicular Tumors and Ovarian Cancer", November 16, 2013, Tirana, Albania.
 - "MRI Characterization of Adnexal Lesions"
 - "Imaging of Ovarian Cancer"
- World Molecular Imaging Society-Harvard Medical School Course on Molecular Imaging: Advanced Molecular Imaging and its Clinical Translation. "Radiogenomics for Cancer". October 27-30, 2013, Boston, MA, USA.
- Mount Sinai Update 2013: "Body and Non-Invasive Vascular Imaging", October 15-16, 2013, New York, NY, USA.

- “Adnexal Masses”
 - “Uterine Malignancies”
- New York Roentgen Ray Society, October 9-11, 2013, New York, NY, USA.
 - “Uterine Malignancies: Staging with MRI”
 - “Diffusion Weighted MRI for Tumor Characterization and Response Monitoring”
- The Society for the Advancement of Women’s Imaging Annual Meeting. September 26-29, 2013, Chicago, IL, USA.
 - “Imaging Endometrial Cancer”
 - “Imaging Cervical Cancer”
- Imaging and Radiation Sciences Program Annual Scientific Retreat on Tumor Microenvironment: Therapeutic Challenges and Opportunities. “Intravoxel Incoherent Motion (IVIM): Implications for Cancer Imaging”. June 17, 2013, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Society of Abdominal Radiology Annual Scientific Meeting and Educational Course. “Uterine Malignancies: The added Value of MRI and PET/CT” February 24 - March 1, 2013, Maui, HI, USA.
- Intensive Pelvic MRI Course. January 14-17, 2013, Melbourne, Australia.
 - “GYN Malignancies Review, FIGO Staging and MRI Protocol Optimization”
 - “GYN Benign Disease Review, Indications for MRI Compared to US and CT”
 - “MRI of Other GU malignancies: Bladder and Vulvar Cancer, What you Need to Know”
 - “Prostate Cancer Imaging & MRI Protocol Optimisation”
- 15th International MRI Symposium. January 24-26, 2013, Garmisch-Partenkirchen, Germany.
 - “MRI in Cervical Carcinoma “
 - “Endometrial Cancer: What is the Added Value of MRI?”
- Grand Rounds Lecture at the Department of Radiology, Brigham and Women’s Hospital and Massachusetts General Hospital, Harvard Medical School. “The Added Value of DWI in Evaluation of Patients with Gynecologic Malignancies”. December 4-5, 2012 Boston, MA, USA.
- Quizmaster, New York Roentgen Society Meeting, November 12, 2012, New York, NY, USA.
- ACRIN Gynecologic Committee, ECOG-ACRIN Meeting. “Functional MRI In Gynecologic Cancer”. November 9-11, 2012, Hollywood, FL, USA.
- The Society for the Advancement of Women’s Imaging, Annual Meeting, “Revised FIGO Staging of Uterine Malignancies: Implications for MR Imaging”. October 18-21, 2012, Chicago, IL, USA.
- 3rd International Meeting on MRI in Oncology: The Role of Magnetic Resonance. “Uterine Tumors”. September 27-28, 2012, Novara, Italy.
- Visiting Professor Lecture at the Department of Radiology, Catholic University, September 25-26, 2012, Rome, Italy.
 - “Imaging of the Acute Female Pelvis”
 - “Uterine Malignancies: the Added Value of MRI in Treatment Selection and Stratification”
 - “The Role of MRI in Characterization of Adnexal Lesions”
 - “Staging Ovarian Cancer: What Technique is Best?”
- European School of Radiology Galen Foundation Course in Oncologic Imaging. “Imaging of Gynecologic Malignancies.” June 21-23, 2012, Athens, Greece.
- Society of Abdominal Radiology Annual Scientific Meeting and Educational Course. “Uterine Malignancies: The Added Value of MRI.” March 26-30, 2012, Phoenix, AZ, USA.

- British Society of Urogenital Radiology Annual Scientific Meeting. "The Evidence for DWI and Clinical Benefits." November 16-17, 2011, Newcastle upon Tyne, UK.
- School of Clinical Radiology. "Ovarian Lesions Differential Diagnosis." November 12, 2011, St. Petersburg, Russia.
- ESMRMB School of MRI Advanced Breast & Female Pelvis MR Imaging. "The Added Value of Functional MRI (DW-MRI and DCE-MRI) in Evaluation of Uterine Malignancies." October 20-22, 2011, Istanbul, Turkey.
- Joint Congress of the Society for Urogenital Radiology and European Society for Urogenital Radiology. "Functional Imaging of the Uterine Malignancies: What it Adds." October 13-16, 2011, Dubrovnik, Croatia.
- UK Radiology Congress. "Imaging Uterine Masses." June 6-8, 2011, Manchester, UK.
- European School of Radiology Galen Foundation Course in Oncologic Imaging. "Imaging of Gynaecologic Malignancies." May 26-28, 2011, Vilnius, Lithuania.
- The Royal Free Hospital Radiology Academic Program. "Clinical Applications of 3T MR Imaging." February 8, 2011, London, UK.
- 14th International MRI Symposium. "Differential Diagnosis of Ovarian Lesions." January 13-15, 2011, Garmisch-Partenkirchen, Germany.
- Radiology Special Lecture Series, Department of Radiology, Memorial Sloan Kettering Cancer Center. "MRI of Uterine Malignancies." December 21, 2010 New York, NY, USA.
- Visiting Professor Lecture at the Department of Radiology, Mount Sinai Medical Center. "MRI of Uterine Malignancies." December 15, 2010, New York, NY, USA.
- Visiting Professor Lecture at the Department of Imaging Sciences, University of Rochester. "MRI of Uterine Malignancies." December 13-14, 2010, Rochester, New York, NY, USA.
- Rochester Roentgen Ray Society. "MRI of the Adnexa: The Essentials and Beyond." December 13, 2010, Rochester, New York, NY, USA.
- 13th Biennial Meeting of the International Gynecologic Cancer Society. "The Added Value of Functional Imaging in the Evaluation of Gynecological Malignancies." October 23-26, 2010, Prague, Czech Republic.
- UK Radiology Congress. "Imaging of the Adnexae." June 7-9, 2010, Birmingham, UK
- Cancer Imaging Perspectives. "3T MR Imaging for Cancer Assessment." May 21, 2010, The Royal Marsden Hospital, London, UK.
- Workshop at the 42nd Davos International Diagnostic Course. "Malignant Diseases of the Female Genital Tract." March 21-26, 2010, Davos, Switzerland.
- East Anglian Radiology Society Annual Meeting. "What's New in Gynaecology MRI?" March 17, 2010, Cambridge, UK.
- Hospital Clinic Barcelona First Update Meeting: Genitourinary Radiology. February 5, 2010, Barcelona, Spain.
 - "Prostate Cancer Imaging"
 - "Value of DWI and DCE in Pelvic Malignancies"
- Gynecological Cancer Intergroup Meeting. "Imaging as an End Point in Clinical Trials." October 10-11, 2009, Belgrade, Serbia.

- European School of Radiology Galen Advanced Course. Women's Cross-Sectional Imaging, Integrated anatomy (US, CT, MRI, PET/CT). September 23-24, 2009, London, UK.
- International Meeting on Advances on Urological Cancer. "Imaging in Prostate Cancer: Evidence and New Developments." September 23-24, 2009, Cambridge, UK.
- 16th ESUR Symposium on Urogenital Radiology. "Limitations of Female Pelvic Ultrasound: When Do You Need MRI/CT?" September 10-13, 2009, Athens, Greece.
- European School of Radiology Galen Foundation Course. Women's Cross-Sectional Imaging, "Imaging of the Pelvis" May 14-16, 2009, Sofia, Bulgaria.
- Society of Abdominal Radiology Annual Scientific Meeting and Educational Course. "MRI of the Uterus" March 15-20, 2009, Maui, HI, USA.
- Conference on Women's Health Imaging, Department of Radiodiagnosis and Imaging, Kasturba Hospital. March 1-3, 2009, Manipal, India
 - "Ovarian Cancer: from Screening to Staging"
 - "MRI of Malignant Uterus: Part I"
 - "MRI of Malignant Uterus: Part II"
 - "MRI and US in Benign Gynecological Conditions"
- GE Healthcare Magnetic Resonance Clinical Symposium. "MRI of Benign Gynecological Conditions." February 28, 2009, Bangalore, India
- Fanfani Institute. "Ovarian Cancer: Screening to Staging." February 19, 2009, Florence, Italy
- Master Class in Advanced Cancer Medicine: Gynecological Cancers, Royal Marsden Hospital. "The Role of MRI in Management of Patients with Gynaecological Tumours". December 8, 2008, London, UK.
- Cambridge Research Institute. "Tumor Morphology and Heterogeneity: Clinical Imaging Perspective. Joint Workshop on Image Processing in Medicine." November 17, 2008, Cambridge, UK.
- Visiting Professor Lecture at the Department of Radiology, McGill University. "The Role of Novel MRI Techniques in Evaluation of Tumour Response to Treatment." October 6-7, 2008, Montreal, Canada.
- Visiting Professor Lecture at the Department of Radiology, McGill University. "MRI of the Adnexa." October 6-7, 2008, Montreal, Canada.
- British Chapter of ISMRM Meeting. "Role of Functional MRI In Evaluation of Response to Treatment In Gynaecological Malignancies." September 4-5, 2008, Newcastle, UK.
- European School of Radiology Galen Advanced Course. Women's Cross-Sectional Imaging, "Integrate Anatomy (US, CT, MRI, PET/CT)." July 4-5, 2008, Berlin, Germany.
- Gynecology Oncology Master Class, British Institute of Radiology. "Cervical Cancer: Diagnosis, Staging, Pitfalls and Protocols." May 2008 London, UK.
- National Cancer Research Institute Gynaecological Translational Subgroup Workshop. "Functional Imaging in Gynaecology Oncology." April 18, 2008, London, UK.
- UK Magnetic Resonance Clinical Symposium. "Clinical body MRI." October 30, 2007, London, UK.
- University of Aberdeen. "Evaluation of Tumour Response to Treatment in Carcinoma of The Cervix." October 5, 2007, Scotland, UK.
- Japanese Society for Magnetic Resonance Imaging Annual Meeting. September 26-29, 2007, Kobe, Japan.
 - "Magnetic Resonance Imaging and Spectroscopy of Prostate Cancer at 1.5 Tesla"

- “Magnetic Resonance Imaging of the Adnexa”
- University of Kyoto. “Magnetic Resonance Imaging of Malignant Uterus” September 25, 2007, Kyoto, Japan.
- Magnetic Resonance Imaging Symposium. August 30-31, 2007, Helsinki, Finland.
 - “Magnetic Resonance Imaging of Prostate Cancer”
 - “Magnetic Resonance Imaging of Gynecological Malignancies”
- Visiting Professor Lecture at the Department of Radiology, Georgetown University. “Imaging of Malignant Uterine Tumors”. February 17, 2007, Washington, DC, USA.
- The Royal Free Hospital Radiology Academic Program. “MRI of the Prostate Revisited.” January 18, 2007, London, UK.
- Gynecology Oncology Master Class, Royal College of Pathologists. “The Role of Imaging in Gynecology Oncology”. December 11, 2006, London, UK.
- European Association of Veterinary Diagnostic Imaging Annual Meeting. “Advances in Body and Pelvic Magnetic Resonance Imaging.” November 17, 2005, Cambridge, UK.
- European Congress of Radiology. “Gastrointestinal Case Presentation in the Junior Image Interpretation Session.” March 4-9, 2004, Vienna, Austria.
- The XIV Paulo Foundation International Symposium. October 6-9, 1999 Turku, Finland.
 - “The Influence of Hormone Replacement Therapy, Smoking, and Diet on Mammographic Parenchymal Patterns”
 - “Common Types of Human Cancer: Current Views of Prevention, Causes, and Treatment of Breast Cancer and Prostate Cancer”

Visiting Professorships

2025	University of Toronto, Canada Stanford University, CA, US
2024	Vita-Salute San Raffaele University, Milan, Italy University of Naples Federico II, Naples, Italy
2022	University of Toronto, Canada Harvard Medical School, Boston, MA, USA
2018	Stanford University, CA, USA
2017	Mount Sinai Medical Center, New York, NY, USA
2016	MD Anderson Cancer Center, Houston, TX, USA Baptist Hospital, Miami, FL, USA University of Kyoto, Kyoto, Japan
2015	Winthrop University Hospital, New York, NY, USA University of Cambridge, Cambridge, UK
2014	Columbia University Medical Center, New York, NY, USA
2012	Harvard Medical School, Boston, MA, USA Università Cattolica del Sacro Cuore, Rome, ITA
2010	Memorial Sloan Kettering Cancer Center, New York, NY, USA University of Rochester, New York, NY, USA Mount Sinai Medical Center, New York, NY, USA

2008
McGill University, Montreal, CAN
Georgetown University, Washington, DC, USA

Editorial Board Member

2025-present
Member, Urologia Journal Honorary Editorial Board

2025-present
Member, The EANM Journal

2024-present
Senior Editor, British Journal of Radiology Artificial Intelligence

2023-present
Member, Scientific Editorial Board, European Radiology
Experimental

2021-2023
Associate Editor, Cancer Research Communications

2020-present
Senior Consulting Editor, Radiology: Artificial Intelligence

2017-2019
Member, Physics & Imaging in Radiation Oncology

2011-2020
Head of Oncology Section, European Radiology

2010-2014
Member, European Medical Imaging Review

2008-2020
Member, European Radiology

2008-2012
Member, Reports in Medical Imaging

Journal Reviewer

2021-present
Nature Communications
Nature Machine Intelligence

2012-present
Radiology
Lancet Oncology

2010-present
International Journal of Gynecological Cancer
European Medical Imaging Review

2008-present
Reports in Medical Imaging
EURORAD
Radiographics
American Journal of Roentgenology

2008-2010
Clinical Oncology

2008
Acta Radiologica

2007-present
Magnetic Resonance in Medicine

2006-Present
Journal of Magnetic Resonance Imaging
European Radiology

2005
Journal of National Cancer Institute

2000-2004
Journal of Medical Screening

BIBLIOGRAPHY

Peer-Reviewed Original Articles

1. Gui B, Russo L, Bharwani N, Cunha TM, Nicolau C, Carnelli C, Fanfani F, Querleu D, Andrieu PC, Lakhman Y, Rizzo S, **Sala E**, Nougaret S, Manganaro L. European Society of Urogenital Radiology (ESUR) guidelines on MR imaging prior to fertility-sparing treatments in patients with cervical, endometrial, and ovarian cancers. *Eur Radiol*, 2025 May 13. doi: 10.1007/s00330-025-11625-x. Online ahead of print.
2. Iezzi R, Contegiacomo A, De Filippis A, Gunn AJ, Atwell T, McClure T, Jing Z, Posa A, Scrofani AR, Maresca A, Madoff DC, Goldberg SN, Kelekis A, Filippiadis D, **Sala E**, Ahmed M. Proceedings from an international consensus meeting on ablation in urogenital diseases. 2024; 15 (1): N/A-N/A. doi:10.1186/s13244-024-01841-2.
3. Giordano C, Marrone L, Romano S, Della Pepa GM, Donzelli CM, Tufano M, Capasso M, Lasorsa VA, Quintavalle C, Guerri G, Martucci M, Auricchio A, Gessi M, **Sala E**, Olivi A, Romano MF, Gaudino S. The FKBP51s Splice Isoform Predicts Unfavorable Prognosis in Patients with Glioblastoma. 2024; 4 (5): 1296-1306. doi:10.1158/2767-9764.CRC-24-0083.
4. Delgado-Ortet M, Bura V, Funingana IG, Hulse D, Rundo L, Brenton J, **Sala E**, Escudero Sanchez L. Imaging-Based Assessment of Response to Olaparib in Platinum-Sensitive Relapsed Ovarian Cancer Patients. *Front Oncol*, 2025 May 1. In review.
5. Beer L, Bura V, Ursprung S, Woitek R, McLean MA, Ang JE, Jimenez-Linan M, Gill AB, Kaggie J, Locke M, Frary A, Field-Rayner J, Patterson I, Reinius M, Graves MJ, Deen S, Funingana G, Rundo L, Priest A, Aloj L, Manavaki R, Mendichovszky IA, Robb F, Schulte RF, Couturier DL, D'Santos CS, Franklin V, Kishore K, Allajbe I, Sauer C, Gallagher FA, Brindle KM, Brenton JD, **Sala E**. Assessment of early response to neoadjuvant chemotherapy in multi-site high-grade serous ovarian cancer using hyperpolarized-¹³C MRI. *EJNMMI Res* 15, 40 (2025). doi:10.1186/s13550-025-01219-5. Online ahead of print.
6. Selby I, Gonzalez Solares E, Breger A, Roberts M, Escudero Sánchez L, Babar J, Rudd JHF, Walton NA, **Sala E**, Schönlieb CB, Weir-McCall JR. A Pipeline for Automated Quality Control of Chest Radiographs. *Radiology: Artificial Intelligence*. 2025 Mar 5. doi:10.1148/ryai.240003. Online ahead of print.
7. Gulli C, Russo L, Gavrilu D, Mangialardi M, Mazzotta G, Mancino M, Autorino R, **Sala E**, Leone A, Gui B. Pelvic insufficiency fractures in locally advanced cervical cancer: the diagnostic yield of post-treatment MRI in a tertiary centre. *Eur J Radiol*. 2025 Jan 9. doi: 10.1016/j.ejrad.2025.111918. Online ahead of print.
8. De Giorgio F, Guerreri M, Gatta R, De Vita V, Mancino M, Boldrini L, **Sala E**, Pascali VL. Exploring radiomic features of lateral cerebral ventricles in postmortem CT for postmortem interval estimation. *Int J Legal Med*. 2024 Dec 20. doi:10.1007/s00414-024-03396-9. Online ahead of print.
9. Infante A, Guerri G, Del Ciello A, Gulli C, Chiloiro S, De Vizio S, Ruscelli L, Merlino B, Natale L, **Sala E**, Gaudino S. Would ChatPDF be advantageous for expediting the interpretation of imaging and clinical articles in PDF format? *J Med Artif Intell*. 2024 Nov 12. doi: 10.21037/jmai-24-153. Online ahead of print.
10. Minordi LM, Franco Sacchetti F, Balzano D, Maresca R, D'Angelo FB, Larosa L, Carano D, Laterza L, Pugliese D, Caprino P, Potenza AE, Scadaferri F, Sofo L, **Sala E**. Clinical, Radiological and Surgical Risk Factors for Endoscopic Anastomotic Recurrence Following Surgery in Crohn's Disease. *J. Clin. Med*. 2024 Nov 6. doi: 10.3390/jcm13226669. In press.
11. Russo L, D'Erme L, Bottazzi S, Amerighi A, Dolcianni M, Bernardini F, De Vincenzo R, Fanfani F, Scambia G, **Sala E**, Gui B. MRI-based assessment of residual disease after neoadjuvant chemotherapy in pregnant women with cervical cancer. *Eur J Radiol*. 2024 Oct 18. doi: 10.1016/j.ejrad.2024.111766. In press.
12. Russo L, D'Erme L, Bottazzi S, Amerighi A, Dolcianni M, Bernardini F, De Vincenzo R, Fanfani F, Scambia G, **Sala E**, Gui B. Evaluating MRI for assessing neoadjuvant chemotherapy response in pregnant patients with cervical cancer: An evidence-based opinion. *Eur J Rad*. 2024 Oct 18. doi: 10.1016/j.ejrad.2024.111766.

13. Le EPV, Wong MYZ, Rundo L, Tarkin JM, Evans NR, Weir-McCall JR, Chowdhury MM, Coughlin PA, Pavey H, Zaccagna F, Wall C, Sriranjn R, Corovic A, Huan Y, Warburton EA, **Sala E**, Roberts M, Schönlie CB, Rudd JHF. Using machine learning to predict carotid artery symptoms from CT angiography: A radiomics and deep learning approach. *Eur Radiol Open*. 2024 Aug 31. doi: 10.1016/j.ejro.2024.100594. In press.
14. Mancino M, Ferrara F, Zanderigo E, Angelino A, Iaccarino L, Belella D, Orlandi A, Belli P, **Sala E** & D'Angelo A. Male breast cancer and sexual aspects research and analysis (MASARA study): preliminary results. *Journal of Medical Imaging and Interventional Radiology*. 2024 Aug 30. doi: 10.1007/s44326-024-00031-0.
15. Leithner D, **Sala E**, Neri E, Schlemmer HP, D'Anastasi M, Weber M, Avesani G, Caglic I, Caruso D, Gabelloni M, Goh V, Granata V, Kunz WG, Nougaret S, Russo L, Woitek R, Mayerhoefer ME. Perceptions of radiologists on structured reporting for cancer imaging-a survey by the European Society of Oncologic Imaging (ESOI). *Eur Radiol*. 2024 Aug;34(8):5120-5130. doi: 10.1007/s00330-023-10397-6. Epub 2024 Jan 11. PMID: 38206405; PMCID: PMC11254975.
16. Boldrini L, Chiloiro G, Di Franco S, Romano A, Smiljanic L, Huong Tran E, Bono F, Charles Davies D, Lopetuso L, De Bonis M, Minucci A, Giacobbe L, Cusumano D, Placidi L, Giannarelli D, **Sala E**, Gambacorta MA. MOREOVER: multiomics MR-guided radiotherapy optimization in locally advanced rectal cancer. *Radiat Oncol*. 2024 Jul 25;19(1):94. doi: 10.1186/s13014-024-02492-9.
17. Russo L, Bottazzi S, Kocak B, Zormpas-Petridis K, Gui B, Stanzione A, Imbriaco M, **Sala E**, Cuocolo R, Ponsiglione A. Evaluating the quality of radiomics-based studies for endometrial cancer using RQS and METRICS tools. *Eur Radiol* 2024 Jul 16. doi: 10.1007/s00330-024-10947-6.
18. Russo L, Pasciuto T, Lupinelli M, Urbano A, D'Erme L, Amerighi A, Fanfani F, Scambia G, Manfredi R, **Sala E**, Ferrandina G, Gui B. The value of MRI in quantification of parametrial invasion and association with prognosis in locally advanced cervical cancer: the "PLACE" study. *Eur Radiol*. 2024 Jun;34(6):4003-4013. doi: 10.1007/s00330-023-10443-3. Epub 2023 Nov 20. PMID: 37981591.
19. Collarino A, Feudo V, Pasciuto T, Florit A, Pfaehler E, de Summa M, Bizzarri N, Annunziata S, Zannoni GF, de Geus-Oei LF, Ferrandina G, Gambacorta MA, Scambia G, Boellaard R, **Sala E**, Rufini V, van Velden FH. Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer? *J Nucl Med*. 2024 Jun 3;65(6):962-970. doi: 10.2967/jnumed.123.267044. PMID: 38548352.
20. Iezzi R, Posa A, Valente I, Contegiacomo A, Zocco MA, Pompili M, Annicchiarico BE, Ponziani FR, Basso M, Goldberg SN, Giulianti F, Gasbarrini A, **Sala E**; HepatoCatt Study Group. Hug sign in intraprocedural cone-beam-CT to predict short-term response to combined treatment of hepatocellular carcinoma. *Radiol Med*. 2024 May;129(5):807-816. doi: 10.1007/s11547-024-01805-y. Epub 2024 Mar 21. PMID: 38512624; PMCID: PMC11088537.
21. Infante A, Gaudino S, Orsini F, Del Ciello A, Gulli C, Merlino B, Natale L, Iezzi R, **Sala E**. Large language models (LLMs) in the evaluation of emergency radiology reports: performance of ChatGPT-4, Perplexity, and Bard. *Clin Radiol*. 2024 Feb;79(2):102-106. doi: 10.1016/j.crad.2023.11.011. Epub 2023 Nov 29.
22. Lancellotta V, Macchia G, Garganese G, Fionda B, Pezzulla D, De Angeli M, Autorino R, Zinicola T, Gui B, Russo L, Fragomeni SM, Ferrandina G, Rovirosa A, **Sala E**, Scambia G, Gambacorta MA, Tagliaferri L. TRImodal DEfinitive invasive vagiNal carcinoma Treatment (TRIDENT protocol): how a standardized approach may change prognostic outcomes. *Int J Gynecol Cancer*. 2024 Feb 5;34(2):197-202. doi: 10.1136/ijgc-2023-004956. PMID: 38290784.
23. Di Pilla A, Nero C, Specchia ML, Ciccarone F, Boldrini L, Lenkowicz J, Alberghetti B, Fagotti A, Testa AC, Valentini V, **Sala E**, Scambia G. A cost-effectiveness analysis of an integrated clinical-radiogenomic screening program for the identification of BRCA 1/2 carriers (e-PROBE study). *Sci Rep*. 2024 Jan 9;14(1):928. doi: 10.1038/s41598-023-51031-1. PMID: 38195911; PMCID: PMC10776619.
24. Buddenkotte T, Rundo L, Woitek R, Escudero Sanchez L, Beer L, Crispin-Ortuzar M, Etmann C, Mukherjee S, Bura V, McCague C, Sahin H, Pintican R, Zerunian M, Allajbeu I, Singh N, Sahdev A, Havrilesky L, Cohn;

- DE, Darcy K, Maxwell GL, Bateman NW, Conrads TP, Freymann JB, Öktem O, Brenton JD, **Sala E**, Schönlieb CB. Deep learning-based segmentation of multisite disease in ovarian cancer. *Eur Radiol Exp*. 2023 Dec 7;7(1):77. doi: 10.1186/s41747-023-00388-z.
25. Panico C, Bottazzi S, Russo L, Avesani G, Celli V, D'Erme L, Cipriani A, Mascilini F, Fagotti A, Scambia G, **Sala E**, Gui B. Prediction of the Risk of Malignancy of Adnexal Masses during Pregnancy Comparing Subjective Assessment and Non-Contrast MRI Score (NCMS) in Radiologists with Different Expertise. *Cancers (Basel)*. 2023 Oct 25;15(21):5138. doi: 10.3390/cancers15215138.
 26. Crispin-Ortuzar M, Woitek R, Reinius MAV, Moore E, Beer L, Bura V, Rundo L, McCague C, Ursprung S, Escudero Sanchez L, Martin-Gonzalez P, Mouliere F, Chandrananda D, Morris J, Goranova T, Piskorz AM, Singh N, Sahdev A, Pintican R, Zerunian M, Rosenfeld N, Addley H, Jimenez-Linan M, Markowetz F, **Sala E**, Brenton JD. Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer. *Nat Commun*. 2023 Oct 24;14(1):6756. doi: 10.1038/s41467-023-41820-7. PMID: 37875466; PMCID: PMC10598212.
 27. Shadbahr T, Roberts M, Stanczuk J, Gilbey J, Teare P, Dittmer S, Thorpe M, Viñas Torné R, **Sala E**, Lió P, Patel M, Preller J, AIX-COVNET Collaboration, Rudd JHF, Mirtti T, Sakari Rannikko A, Aston JAD, Tang J, Schönlieb CB. The impact of imputation quality on machine learning classifiers for datasets with missing values. *Commun Med (Lond)*. 2023 Oct 6;3(1):139. doi: 10.1038/s43856-023-00356-z.
 28. Escudero Sanchez L, Buddenkotte T, Al Sa'd M, McCague C, Darcy J, Rundo L, Samoshkin A, Graves MJ, Hollamby V, Browne P, Crispin-Ortuzar M, Woitek R, **Sala E**, Schönlieb CB, Doran SJ, Oktem O. Integrating Artificial Intelligence Tools in the Clinical Research Setting: The Ovarian Cancer Use Case. *Diagnostics* 2023, 13 (18) 2813. doi: org/10.3390/diagnostics13172813.
 29. Buddenkotte T, Escudero Sanchez L, Crispin-Ortuzar M, Woitek R, McCague C, Brenton JD, Oktem O, **Sala E**, Rundo L. Calibrating ensembles for scalable uncertainty quantification in deep learning-based medical image segmentation. *Computers in Biology and Medicine*. 2023 Jun 9; Vol. 163 (107396). doi: 10.1016/j.combiomed.2023.107096.
 30. Lococo F, Boldrini L, Diepriye CD, Evangelista J, Nero C, Flamini S, Minucci A, de Paolis E, Vita E, Cesario A, Annunziata S, Calcagni ML, Chiappetta M, Cancellieri A, Larici AR, Cicchetti G, Troost EGC, Roza A, Farré N, Ozturk E, van Doorne D, Leoncini F, Urbani A, Trisolini R, Bria E, Giordano A, Rindi G, **Sala E**, Tortora G, Valentini V, Boccia S, Margaritora S, Scambia G. Lung Cancer Multi-omics Digital Human Avatars for Integrating Precision Medicine Into Clinical Practice (LANTERN). *BMC Cancer*, 2023, 23 (1) 540. doi: 10.1186/s12885-023-10997-x.
 31. Abdar M, Mehrzadi A, Goudarzi M, Masoudkabar F, Rundo L, Mamouei M, **Sala E**, Khosravi A, Makarenkov V, Rajendra Acharya U, Saadatagah S, Naderian M, García S, Sarrafzadegan N, Nahavandi S. Binarized multi-gate mixture of Bayesian experts for cardiac syndrome X diagnosis: A clinician-in-the-loop scenario with a belief-uncertainty fusion paradigm. *Information Fusion*. 2023 Sept. Vol. 97, 101813. doi: 10.1016/j.inffus.2023.101813.
 32. Breger A, Selby I, Roberts M, Babar J, Gkrania-Klotsas E, Preller J, Escudero Sánchez L; AIX-COVNET Collaboration; Rudd JHF, Aston JAD, Weir-McCall JR, **Sala E**, Schönlieb CB. A pipeline to further enhance quality, integrity and reusability of the NCCID clinical data. *Sci Data*. 2023 Jul 27;10(1):493. doi: 10.1038/s41597-023-02340-7. PMID: 37500661; PMCID: PMC10374610.
 33. Yeung M, Rundo L, Nan Y, **Sala E**, Schönlieb CB, Yang G. Calibrating the Dice Loss to Handle Neural Network Overconfidence for Biomedical Image Segmentation. *J Digital Imag*. 2023 Apr. Vol.36, 739–752 (2023). doi: 10.1007/s10278-022-00735-3
 34. Delgado-Ortet M, A V Reinius M, McCague C, Bura V, Woitek R, Rundo L, Gill AB, Gehrung M, Ursprung S, Bolton H, Haldar K, Pathiraja P, Brenton JD, Crispin-Ortuzar M, Jimenez-Linan M, Escudero Sanchez L, **Sala E**. Lesion-specific 3D-printed moulds for image-guided tissue multi-sampling of ovarian tumours: A prospective pilot study. *Front Oncol*. 2023 Feb 13; 13:1085874. doi: 10.3389/fonc.2023.1085874.

35. Sushentsev N, Rundo L, Abrego L, Li Z, Nazarenko T, Warren AY, Gnanapragasam VJ, **Sala E**, Zaikin A, Barrett T, Blyuss O. Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance. *Eur Radiol.* 2023 Feb 7; 33, 3792–3800. doi: 10.1007/s00330-023-09438-x.
36. Escudero Sanchez L, Brown E, Rundo L, Ursprung S, **Sala E**, Bohndiek SE, Partarrieu IX. "Publisher Correction: Feasibility and sensitivity study of radiomic features in photoacoustic imaging of patient-derived xenografts". *Sci Rep.* 2022 November 30; 12 (2022) 20657. doi: [10.1038/s41598-022-24697-2](https://doi.org/10.1038/s41598-022-24697-2).
37. Sanchez LE, Brown E, Rundo L, Ursprung S, **Sala E**, Bohndiek SE, Partarrieu IX. Feasibility and sensitivity study of radiomic features in photoacoustic imaging of patient-derived xenografts. *Sci Rep.* Sep 2022 9; 12 (1)15142. doi: 10.1038/s41598-022-19084-w.
38. Usher-Smith JA, Godoy A, Burge SW, Burbidge S, Cartledge J, Crosbie PAJ, Eckert C, Farquhar F, Hammond D, Hancock N, Iball GR, Kimuli M, Masson G, Neal RD, Rogerson S, Rossi SH, **Sala E**, Smith A, Sharp SJ, Simmonds I, Wallace T, Ward M, Callister MEJ, Stewart GD. "The Yorkshire Kidney Screening Trial (YKST): protocol for a feasibility study of adding non-contrast abdominal CT scanning to screen for kidney cancer and other abdominal pathology within a trial of community-based CT screening for lung cancer." *BMJ Open* 2022 12(9): e063018.
39. Sedlacek O, Kleesiek J, Gallagher FA, Murray J, Prinz S, Perez-Lopez R, **Sala E**, Caramella S, Diffetock S, Lassau N, Priest AN, Suzuki C, Vargas R, T. Giandini T, Vaiani M, Messina A, Blomqvist L, Beets-Tan RGH, Oberrauch P, Schlemmer HP, Bach M. Quantification and reduction of cross-vendor variation in multicenter DWI MR-imaging: Results of the Cancer Core Europe Imaging Task Force. *Eur Radiol* 2022 Jun 9. doi: 10.1007/s00330-022-08880-7. Epub ahead of print. PMID: 35678860.
40. Rundo L, Beer L, Sanchez L, Crispin-Ortuzar M, Reinius M, McCague C, Sahin H, Bura V, Pintican R, Zerunian M, Addley H, Martin-Gonzalez P, Buddenkotte T, Singh N, Sahdev A, Funingana G, Jimenez-Linan M, Markowetz F, Brenton J, **Sala E**, Woitek R. Clinically interpretable radiomics-based prediction of histopathologic response to neoadjuvant chemotherapy in high-grade serous ovarian carcinoma. *Frontiers in Oncology* 2022 Jun 16;12:868265. doi: 10.3389/fonc.2022.868265. PMID: 35785153; PMCID: PMC9243357.
41. Wibmer AG, Lefkowitz R, Lakhman Y, Chaim J, Nikolovski I, **Sala E**, Fine SW, Donahue TF, Cattan M, Hricak H, Vargas AH. MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy. *Clinical Genitourinary Cancer*, 2022, <https://doi.org/10.1016/j.clgc.2022.04.001>.
42. Ursprung S, Woitek R, McLean MA, Priest AN, Crispin-Ortuzar M, Brodie CR, Gill AB, Gehrung M, Beer L, Riddick ACP, Field-Rayner J, Grist JT, Deen SS, Riemer F, Kaggie JD, Zaccagna F, Duarte JAG, Locke MJ, Frary A, Aho TF, Armitage JN, Casey R, Mendichovszky JA, Welsh SJ, Barrett T, Graves MJ, Eisen T, Mitchell TJ, Warren AY, Brindle KM, **Sala E**, Stewart GD, Gallagher FA. Hyperpolarized ¹³C-pyruvate metabolism as a surrogate for tumor grade and poor outcome in renal cell carcinoma – a proof of principle study. *Cancers* 2022, 14(2), 335; <https://doi.org/10.3390/cancers14020335>.
43. Wibmer AG, Nikolovski I, Chaim J, Lakhman Y, Lefkowitz R, **Sala E**, Carlsson SV, Fine SW, Cattan M, Hricak H, Vargas AH. Local extent of prostate cancer on MRI vs. prostatectomy histopathology: associations with long-term oncologic outcomes. *Radiology* 2022 Mar;302(3):595-602. doi: 10.1148/radiol.210875.
44. Sushentsev N, Caglic I, Rundo L, Kozlov V, **Sala E**, Gnanapragasam VJ, Barrett T. Serial changes in tumour measurements and apparent diffusion coefficients in prostate cancer patients on active surveillance with and without histopathological progression. *Br J Radiol* 2022 Mar 1;95(1131):20210842. doi: 10.1259/bjr.20210842.
45. Woitek R, McLean M, Ursprung S, Rueda OM, Manzano Garciae R, Locke M, Beer L, Baxter G, Rundo L, Provenzano E, Kaggie J, Patterson A, Frary A, Field-Rayner J, Papalouka V, Kane J, Benjamin A, Gill AB, Priest A, Lewis D, Russelle R, Grimmer A, White B, Latimer-Bowman B, Patterson I, Schiller A, Carmo B, Slough R, Titus Lanzk, Wason J, Schulte R, Chine SF, Graves MJ, Gilbert FJ, Abraham JE, Caldas C, Brindle KM, **Sala E**, Gallagher F. Hyperpolarized carbon-13 MRI for early response assessment of

- neoadjuvant chemotherapy in breast cancer patients. *Cancer Res.* 2021 Dec 1; 81(23): 6004–6017. doi: 10.1158/0008-5472.CAN-21-1499.
46. de Farias EC, di Noia C, Han C, **Sala E**, Castelli M, Rundo L. Impact of GAN-based Lesion-Focused Medical Image Super-Resolution on the Robustness of Radiomic Features. *Nat Sci Rep* 11, 21361 (2021). <https://doi.org/10.1038/s41598-021-00898-z>.
 47. Ursprung S, Mossop H, Gallagher FA, **Sala E**, Skells R, Sipple JAN, Mitchell TJ, Chhabra A, Fife K, Matakidou A, Young G, Walker A, Thomas MG, Ortuzar MC, Sullivan M, Protheroe A, Oades G, Venugopal B, Warren AY, Stone J, Eisen T, Wason J, Welsh SJ, Stewart GD. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol. *BMC Cancer* 2021 Nov; 21: 1238 | PMID: 34794412.
 48. Yeung M, **Sala E**, Schönlieb CB, Rundo L. Unified Focal loss: Generalising Dice and cross entropy-based losses to handle class imbalanced medical image segmentation. *Computerized Medical Imaging and Graphics*, 2021: 95:102026. DOI: 10.1016/j.compmedimag.2021.102026.
 49. Yeung M, **Sala E**, Schönlieb CB, Rundo L. Focus U-Net: A novel dual attention-gated CNN for polyp segmentation during colonoscopy. *Comput Biol Med.* 2021 Oct; 137: 104815. doi: 10.1016/j.compbiomed.2021.104815.
 50. Rundo L, Ledda RE, di Noia C, **Sala E**, Mauri G, Milanese G, Sverzellati N, Apolone G, Gilardi MC, Messa MC, Castiglioni I, Pastorino U. A Low-dose CT-based Radiomic Model to Improve Characterization and Screening Recall Intervals of Indeterminate Prevalent Pulmonary Nodules. *Diagn.* 2021 Sep 3;11(9). <https://doi.org/10.3390/diagnostics11091610>.
 51. Tardieu M, Lakhman Y, Khellaf L, Cardoso M, Sgarbura O, Colombo PE, Crispin-Ortuzar M, **Sala E**, Goze-Bac C, Stephanie Nougaret S. Assessing Histology Structures by Ex Vivo MR Microscopy and Exploring the Link Between MRM Derived Radiomic Features and Histopathology in Ovarian Cancer. *Front Oncol* 2021; 11: 771848 | PMID: 35127479.
 52. Sushentsev N, Rundo L, Blyuss O, Nazarenko T, Aleksandr Suvorov A, Gnanapragasam VJ, **Sala E**, Barrett T. Comparative performance of MRI-derived PRECISE scores and delta-radiomics models for the prediction of prostate cancer progression in patients on active surveillance. *Eur Radiol* 2021, <https://doi.org/10.1007/s00330-021-08151-x>.
 53. Sushentsev N, Rundo L, Blyuss O, Gnanapragasam VJ, **Sala E**, Barrett T. MRI-derived radiomics model for baseline prediction of prostate cancer progression on active surveillance. *Nature Scientific Reports* 2021, 11, 12917. <https://doi.org/10.1038/s41598-021-92341-6>.
 54. van Eijnatten M, Rundo L, Batenburg KJ, Lucka F, Beddowes E, Caldas C, Gallagher FA, **Sala E**, Schonlieb CB, Woitek R. 3D deformable registration of longitudinal abdominopelvic CT images using unsupervised deep learning. *Computer Methods and Programs in Biomedicine* 2021, doi: <https://doi.org/10.1016/j.cmpb.2021.106261>.
 55. Mottola M, Ursprung S, Rundo L, Escudero Sanchez L, Klatte T, Mendichovszky I, Stewart GD, **Sala E**, Bevilacqua A. Reproducibility of CT-based radiomic features against image resampling and perturbations for tumour and healthy kidney in renal cancer patients. *Nature Scientific Reports* 2021, 11, 11542 (2021). <https://doi.org/10.1038/s41598-021-90985-y>.
 56. Sahin H, Panico C, Ursprung S, Simeon V, Chiodini P, Frary A, Carmo B, Smith J, Freeman S, Jimenez-Linan M, Bolton H, Haldar K, Ang JE, Reinhold C, **Sala E**, Addley HA*. Non-contrast MRI can accurately characterize adnexal masses: a retrospective study. *Eur Radiol*, 2021 Mar 16. doi: 10.1007/s00330-021-07737-9.

57. Han C, Rundo L, Murao K, Noguchi T, Shumahara Y, Milacski Z.Á, Koshino S, **Sala E**, Nakayama H, Satoh S. MADGAN: unsupervised medical anomaly detection GAN using multiple adjacent brain MRI slice reconstruction. *BMC Bioinformatics*, 2021;22, 31. <https://doi.org/10.1186/s12859-020-03936-1>.
58. Escudero Sanchez L, Rundo L, Gill AB, Hoare M, Serrao EM, **Sala E**. "Robustness of radiomic features in CT images with different slice thickness, comparing liver tumour and muscle" *Nature Scientific Reports* 2021, 11, 8262. <https://doi.org/10.1038/s41598-021-87598-w>.
59. Wang G, Liu X, Shen J, Deng R, Yang J, Ye L, Wu X, Zhou Z, Zhang X, Wang C, Li Z, Liang W, Zheng L, Sang Y, Yu T, Gao M, Wang J, Yang Z, Cai H, Lu G, Zhang L, Yang L, Xu W, Wang W, Olevera A, Ziyar I, Zhang C, Li O, Liao W, Liu J, Chen W, Chen W, Shi J, Zhang L, Yan Z, Zhou X, Lin G, Cao G, Lau LL, Mo L, Roberts M, **Sala E**, Schönlieb CB, Fok M, Lau JYN, He J, Li W, Chen T, Zhang K, Lin T. A deep-learning pipeline for the diagnosis and discrimination of viral, non-viral and COVID-19 pneumonia from chest X-ray images. *Nature Biomedical Engineering* 2021, <https://doi.org/10.1038/s41551-021-00704-1>.
60. Bai X, Wang H, Ma L, Xu Y, Gan J, Fan Z, Yang F, Ma K, Yang J, Bai S, Shu C, Zou X, Huang R, Zhang C, Liu X, Tu D, Xu C, Zhang W, Wang X, Chen A, Zeng Y, Yang D, Wang M, Holalkere N, Halin NJ, Kamel IR, Wu J, Peng X, Wang X, Shao J, Mongkolwat P, Zhang J, Liu W, Robert M, Teng Z, Beer L, Sanchez LE, **Sala E**, Rubin DL, Weller A, Lasenby J, Zheng C, Wang J, Li Z, Schönlieb C, Xia T. Advancing COVID-19 Diagnosis with Privacy-Preserving Collaboration in Artificial Intelligence. *Nat Mach Intell* 2021; 3: 1081–1089. <https://doi.org/10.1038/s42256-021-00421-z>.
61. Le E, Rundo L, Evans NR, Tarkin J M, Chowdhury MM, Coughlin P, Pavey H, Wall C, Zaccagna F, Gallagher FA, Huang Y, Sriranjani R, Le A, Weir-Mccall JR, Roberts M, Gilbert F, Waburton EA, Schonlieb CB, **Sala E**, Rudd JHF. Assessing robustness of carotid artery CT angiography radiomics in the identification of culprit lesions in cerebrovascular events. *Nature Scientific Reports*, 2021, <https://doi.org/10.1038/s41598-021-82760-w>.
62. Wibmer AG, Chaim J, Lakhman Y, Lefkowitz R, Nincevic J, Nikolovski I, **Sala E**, Gonen M, Carlsson SV, Fine SW, Zelefsky M, Scardino P, Hricak H, Vargas AH. Oncologic outcomes after localized prostate cancer treatment: associations with pretreatment prostate magnetic resonance imaging findings. *J Urology* 2021 Apr;205(4):1055-1062. doi: 10.1097/JU.0000000000001474.
63. Rundo L, Tangherloni A, Cazzaniga P, Mitri M, Galimberti S, Woitek R, **Sala E**, Mauri G, Nobile MS. A CUDA-powered method for the feature extraction and unsupervised analysis of medical images. *The Journal of Supercomputing* 2021, <https://doi.org/10.1007/s11227-020-03565-8>.
64. Veeraraghavan H*, Vargas HA*, Sanchez A, Micco M, Mema E, Lakhman Y, Crispin-Ortuzar M, Huang EP, Levine DA, Grisham RN, Abu-Rustum N, Deasy JO, Snyder A, Miller ML, Brenton JD*, **Sala E***. Integrated multi-tumor radiogenomic marker of outcomes in patients with high serous ovarian carcinoma. *Cancers* 2020, 12(11), 3403; <https://doi.org/10.3390/cancers12113403>.
65. Gill A, Rundo L, Wan J, Lau D, Zawaideh J, Woitek R, Zaccagna F, Beer L, Gale D, **Sala E**, Couturier D, Corrie P, Rosenfeld N, Gallagher F. Correlating radiomic features of heterogeneity on CT with circulating tumor DNA in metastatic melanoma. *Cancers* 2020,12(12), 3493; <https://doi.org/10.3390/cancers12123493>.
66. Beer L, Martin-Gonzales P, Delgado-Ortet M, Reinus M, Rundo L, Woitek R, Ursprung S, Escudero L, Sahin H, Lawton T, Phadke G, Davey S, Funingana G, Ang JE, Jimenez-Lina M, Markowitz F, Nguyen NQ, Benton JD, Addley H, **Sala E**. Ultrasound-guided targeted biopsies of CT based radiomic tumour habitats: Technical Development and Initial Experience in metastatic ovarian cancer. *Eur Radiol*, 2020, <https://doi.org/10.1007/s00330-020-07560-8>.
67. Serrao EM, Kessler DA, Carmo C, Beer L, Brindle KM, Buonincontri G, Gallagher FA, Gilbert FJ, Godfrey E, Graves MJ, McLean M, **Sala E**, Schulte RF, Kaggie J. Magnetic Resonance fingerprinting of the pancreas at 1.5T and 3.0T. *Scientific Reports*, 2020, <https://doi.org/10.1038/s41598-020-74462-6>.
68. Han C, Rundo L, Murao K, Milacski Z.Á, Umemoto K, **Sala E**, Nakayama H, Satoh S. GAN-based multiple adjacent brain MRI slice reconstruction for unsupervised Alzheimer's disease diagnosis". In: *Proc.*

69. Crispin-Ortuzar M, Gehrung M, Ursprung S, Gill AB, Warren AY, Beer L, Gallagher FA, Mitchell TJ, Mendichovszky IA, Priest AN, Stewart GD*, **Sala E***, Markowetz F*. Three-dimensional printed molds for image-guided surgical biopsies: an open source computational platform. *JCO Clin Cancer Inform* 2020; 4:736-748.
70. Caglic I, Sushentsev N, Gnanapragasam VJ, **Sala E**, Shaida N, Koo BC, Kozlov V, Warren AY, Kastner C, Barrett B. MRI-derived PRECISE scores for predicting pathologically-confirmed radiological progression in prostate cancer patients on active surveillance. *Eur Radiol*, 2020; <https://doi.org/10.17863/CAM.55752>.
71. Jiménez-Sánchez A, Cybulska P, LaVigne K, Koplev S, Cast O, Couturier DL, Memon D, Selenica P, Nikolovski I, Mazaheri Y, Bykov Y, Geyer FC, Macintyre G, Gavarró LM, Drews RM, Gill MB, Papanastasiou AD, Sosa ER, Soslow RA, Walther T, Shen R, Chi DS, Park KJ, Hollmann T, Reis-Filho JS, Markowetz F, Beltrao P, Vargas HA, Zamarin D, Brenton JD, Snyder A, Weigelt B, **Sala E**, Miller M. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. *Nat Genet*, 2020; Jun;52(6):582-593. doi: 10.1038/s41588-020-0630-5.
72. Woitek R, McLean MA, Gill AB, Grist JT, Provenzano E, Patterson AJ, Ursprung S, Torheim T, Zaccagna F, Locke M, Laurent M-C, Hilborne S, Frary A, Beer L, Rundo L, Patterson I, Slough R, Kane J, Biggs H, Harrison E, Lanz T, Basu B, Baird R, **Sala E**, Graves MJ, Gilbert FJ, Abraham JE, Caldas C, Brindle KM, Gallagher FA. Hyperpolarized ¹³C-MRI of tumor metabolism demonstrates early metabolic response to neoadjuvant chemotherapy in breast cancer. *Radiology: Imaging Cancer*, 2020; <https://doi.org/10.1148/rycan.2020200017>.
73. Rundo L, Beer L, Ursprung S, Martin-Gonzalez P, Markowetz F, Brenton JD, Crispin-Ortuzar M, **Sala E**, Woitek R. Tissue-specific and interpretable sub-segmentation of whole tumour burden on CT images by unsupervised fuzzy clustering. *Computers in Biology and Medicine*, 2020; <https://doi.org/10.1016/j.combiomed.2020.103751>.
74. Zawaideh JP, **Sala E**, Shaida N, Koo B, Warren AY, Carmisciano L, Saeb-Parsy K, Gnanapragasam VJ, Kastner C, Barrett T. Diagnostic accuracy of biparametric versus multiparametric MRI: assessment of contrast benefits in clinical practice. *Eur Radiol*, 2020 Jul;30(7):4039-4049; <https://doi.org/10.1007/s00330-020-06782-0>.
75. Beer L, Sahin H, Bateman NW, Blazic I, Vargas HA, Veeraraghavan H, Kirby J, Fevrier-Sullivan B, Freymann JB, Jaffe C, Brenton JD, Miccò M, Nougaret S, Darcy KM, Maxwell LG, Conrads TP, Huang E, **Sala E**. Integration of proteomics with CT-based qualitative and texture features in high-grade serous ovarian cancer patients: an exploratory analysis. *Eur Radiol*, 2020; 30(8), 4306-4316. <https://doi.org/10.1007/s00330-020-06755-3>.
76. Smith CG, Moser T, Mouliere F, Field-Rayner J, Eldridge I, Riediger AL, Chandrananda D, Heider K, Wan JCM, Warren AY, Morris J, Hudecova I, Cooper WN, Mitchell TJ, Gale D, Ruiz-Valdepenas A, Klatte T, Ursprung S, **Sala E**, Riddick ACP, Aho TF, Armitage JN, Perakis S, Pichler M, Seles M, Wcislo G, Welsh SJ, Matakidou A, Eisen T, Massie CE, Rosenfeld N, Heitzer E, Stewart GD. Comprehensive characterisation of cell-free tumour dna in plasma and urine of patients with renal tumours. *Genome Medicine*, 2020 Feb 28;12(1):23. doi: 10.1186/s13073-020-00723-8.
77. Sushentsev N, Caglic I, **Sala E**, Shaida N, Slough RA, Carmo B, Kozlov V, Gnanapragasam V, Barrett T. The effect of capped biparametric magnetic resonance imaging slots on weekly prostate cancer imaging workload. *Br J Radiol* 2020 Feb 3;20190929. <https://doi.org/10.1259/bjr.20190929>.
78. Ursprung S, Beer L, Bruining A, Woitek R, Stewart GD, Gallagher FA, **Sala E**. Radiomics of computed tomography and magnetic resonance imaging in renal cell carcinoma – a systematic review and meta-analysis. *Eur Radiol*, 2020 Jun;30(6):3558-3566. doi: 10.1007/s00330-020-06666-3.

79. Gallagher FA, Woitek R, McLean MA, Gill A, Manzano Garcia R, Provenzano E, Riemer F, Kaggie J, Chhabra A, Ursprung S, Grist JT, Daniels CJ, Zaccagna F, Laurent MC, Locke M, Hilborne S, Frary A, Torheim T, Boursnell C, Schiller A, Patterson I, Slough R, Carmo B, Kane J, Biggs H, Deen SS, Patterson A, Lanz T, Kingsbury Z, Ross M, Basu B, Baird R, Lomas DJ, **Sala E**, Wason J, Rueda OM, Chin SF, Wilkinson IB, Graves MJ, Abraham J, Gilbert FJ, Caldas C, Brindle KM. Imaging breast cancer using hyperpolarized Carbon-13 MRI. *PNAS* 2020, Jan 28;117(4):2092-2098, <https://doi.org/10.1073/pnas.1913841117>.
80. Himoto Y, Cybulska P, Shitano F, **Sala E**, Zheng J, Capanu M, Nougaret S, Nikolovski I, Vargas HA, Wang W, Mueller JJ, Chi DS, Lakhman Y. Does The method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer? *Gynec Onc* 2019 Sep 12. pii: S0090-8258(19)31462-3. 155(2):192-200, <https://doi.org/10.1016/j.ygyno.2019.08.011>.
81. Deen S, Priest A, McLean MA, Gill AB, Brodie CR, Crawford R, Latimer J, Baldwin P, Earl HM, Parkinson CA, Smith SA, Hodgkin C, Patterson I, Addley HC, Freeman SJ, Moyle PL, Jimenez-Linan M, Graves MJ, **Sala E**, Brenton JD, Gallagher F. Diffusion Kurtosis MRI as a predictive biomarker of response to neoadjuvant chemotherapy in high grade serous ovarian cancer. *Sci Reports* 2019; 9:10742. <https://doi.org/10.1038/s41598-019-47195-4>.
82. Himoto Y, Veeraraghavan H, Zheng J, Zamarin D, Snyder A, Capanu M, Nougaret S, Vargas HA, Shitano F, Callahan M, Wang W, **Sala E**, Lakhman Y*. Computed tomography-derived radiomic metrics can identify responders to immunotherapy in ovarian cancer. *JCO PO* 2019;3:1-13. 10.1200/PO.19.00038.
83. Barrett T, Slough R, Sushentsev N, Shaida N, Koo BC, Caglic I, Kozlov V, Warren AY, Thankappannair V, Pinnock C, Shah N, Saeb-Parsy K, Gnanapragasam VJ, **Sala E**, Kastner C. Three-year experience of a dedicated prostate MpMRI pre-biopsy programme and effect on timed cancer diagnostic pathways. *Clin Rad* 2019;894,e1-894,e9. <https://doi.org/10.1016/j.crad.2019.06.004>.
84. Deen S, Riemer F, McLean MA, Gill AB, Kaggie J, Grist JT, Crawford R, Latimer J, Baldwin P, Earl HM, Parkinson CA, Smith SA, Hodgkin C, Moore E, Jimenez-Linan M, Brodie CR, Addley HC, Freeman SJ, Moyle PL, **Sala E**, Graves MJ, Brenton JD, Gallagher F. Sodium MRI with 3D-cones as a measure of tumour cellularity in high grade serous ovarian cancer. *Eur J Radiol Open* 2019 Apr 19;6:156-162. <https://doi.org/10.1016/j.ejro.2019.04.001>.
85. Weigelt B, Vargas HA, Selenica P, Geyera PC, Mazaheri Y, Blecua P, Conlon N, Hoang LN, Jungbluth AA, Snyder A, Ng CKY, Papanastasiou AD, Sosa RA, Soslow RA, Chi DS, Gardner GJ, Shen R, Reis-Filho JS, **Sala E**. Radiogenomics analysis of intra-tumor heterogeneity in a patient with high-grade serous ovarian cancer. *JCO PO* 2019;3:1-9. <https://doi.org/10.1200/PO.18.00410>.
86. Kaggie J, Deen S, Kessler DA, McLean MA, Buonincontri G, Schulte RF, Addley H, **Sala E**, Brenton JD, Graves MJ, Gallagher F. Feasibility of quantitative magnetic resonance fingerprinting in ovarian tumours for T1 and T2 mapping. *IEEE Transactions on Radiation and Plasma Medical Sciences*, 2019;3:509-515. <https://doi.org/10.1109/TRPMS.2019.2905366>.
87. Barrett T, Lawrence EM, Priest A, Warren AY, Gnanapragasam VJ, **Sala E**. Repeatability of diffusion-weighted MRI of the prostate using whole lesion adc values, skew and histogram analysis. *Eur J Radiol*, 2019; 110:22–29. <https://doi.org/10.1016/j.ejrad.2018.11.014>.
88. Bodo S*, Campagne S*, Htwe Thin T*, Higginson1 DS*, Vargas HA*, Hua G, Fuller JD, Ackerstaff E, Russell J, Klingler S, Cho H, Kaag M, Mazaheri Y, Rimner1 A, Manova-Todorova K, Epel B, Zatzky J, Cleary CR, Rao SS, Yamada Y, Zelefsky MJ, Halpern7 HJ, Koutcher JA, Cordon-Cardo C, Greco C, Haimovitz-Friedman A, **Sala E***, Powell SN*, Kolesnick R*, Fuks Z*. Single dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. *J Clin Invest*. 2019 Feb 1;129(2):786-801. <https://doi.org/10.1172/JCI97631>.
89. Meyer A, Veeraraghavan H, Nougaret S, Lakhman Y, Sosa, R, Soslow RA, Sutton EJ, Hricak H, **Sala E**, Vargas HA. Association between CT-texture-derived tumor heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer. *Abdominal Radiology*. 2019 Jun;44(6):2040-2047. <https://doi.org/10.1007/s00261-018-1840-5>.

90. Horvat N, Veeraraghavan H, Khan M, Blazic I, Zheng J, Capanu M, **Sala E**, Garcia-Aguilar J, Gollub MJ, Petkovska I. MR imaging of rectal cancer: radiomic analysis to assess treatment response after neoadjuvant therapy. *Radiology* 2018; 287(3):833-843. <https://doi.org/10.1148/radiol.2018172300>.
91. Nougaret S, Lakhman Y, Molinari N, Feier D, Scelzo C, Vargas HA, Sosa RE, Hricak H, Soslow RA, Grisham RN, **Sala E**. CT imaging features defining key differences between serous borderline ovarian tumors and low-grade serous ovarian cancers. *AJR* 2018; 210(4):918-926. <https://doi.org/10.2214/AJR.17.18254>.
92. Cybulska P, Jimenez-Sanchez A, LaVigne K, Walther T, Vargas HA, Zivanovic O, Weigelt B, **Sala E**, Miller M, Snyder A. Gene set enrichment clustering and the tumor microenvironment in primary high-grade serous ovarian cancer (HGSOC). *Gynecol Oncol*. 149: 25-25. [10.1016/j.ygyno.2018.04.061](https://doi.org/10.1016/j.ygyno.2018.04.061).
93. Jiménez-Sánchez A, Memmon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Walther T, Aghajanian C, Wolchok J, **Sala E**, Merghoub T, Snyder A, Miller ML. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. *Cell* 2017;170(5):927-938.
94. Vargas HA, Huang EP, Lakhman Y, Ippolito JE, Bhosale P, Mellnick V, Shinagare A, Anello M, Kirby J, Fevrier-Sullivan B, Freymann J, Jaffe CC, **Sala E**. Radiogenomics of high-grade serous ovarian cancer: multi-reader multi-institutional study from The Cancer Genome Atlas-Ovarian Cancer (TCGA-OV) Imaging Research Group. *Radiology* 2017; 285(2):482-492.
95. Nougaret S, Lakhman Y, Gönen M, Goldman DA, Miccò M, D'Anastasi M, Johnson SA, Juluru K, Arnold AG, Sosa RE, Soslow RA, Vargas HA, Hricak H, Kauff ND, **Sala E**. Associations between BRCA mutation status, CT imaging phenotypes and clinical outcomes in women with high-grade serous ovarian cancer. *Radiology* 2017;285(2):472-481.
96. Nougaret S, Robertson N, Golia Pernicka J, Milinari N, Hotker A, Ehdale B, **Sala E**, Hricak H, Vargas HA. The Performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer. *Abdom Radiol* 2017;42(7):1968-1974.
97. Vargas HA, Veeraraghavan H, Micco M, Nougaret S, Lakhman Y, Meier AA, Sosa R, Soslow RA, Levine DA, Weigelt B, Aghajanian C, Hricak H, Deasy J, Snyder A, **Sala E**. A novel representation of inter-site tumor heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. *Eur Radiol* 2017;27(9):3991-4001.
98. Robertson N, **Sala E**, Benz M, Landa J, Scardino P, Scher H, Hricak H, Vargas HA. Combined whole-body and multi-parametric prostate MRI as a single-step approach for the simultaneous assessment of local recurrence and metastatic disease after radical prostatectomy. *J Urol*. 2017 198:65-70.
99. Nicolau C, **Sala E**, Kumar A, Goldman DA, Schoder H, Hricak H, Vargas HA. Renal masses detected on FDG PET/CT in patients with lymphoma: imaging features differentiating primary renal cell carcinomas from renal lymphomatous involvement. *AJR* 2017, 208 (4): 849-853. doi: 10.2214/AJR.16.17133.
100. Vargas HA, Schor RS, Long N, Kirzner AN, Cunningham JD, Goldman DA, Maoskowitz, CS, Sosa RE, **Sala E**, Panicek DM, Hricak HH. Prostate cancer bone metastases on staging prostate MRI: prevalence and clinical features associated with their diagnosis. *Abdom Radiol* 2017 Jan;42(1):271-277. <https://doi.org/10.1007/s00261-016-0851-3>
101. Yarmish G, **Sala E**, Goldman D, Lakhman Y, Soslow R, Hricak H, Gardner G, Vargas HA. Abdominal wall endometriosis: differentiation from other masses using CT features. *Abdom Radiol* 2017 May;42(5):1517-1523.
102. Lakhman Y, Veeraraghavan H, Chaim J, Feier D, Goldman DA, Moskowitz CS, Nougaret S, Sosa RE, Vargas HA, Soslow R, Hricak H, Abu-Rustum NR, **Sala E**. Differentiation of uterine leiomyosarcoma from atypical leiomyoma: diagnostic accuracy of qualitative MR imaging features and role of texture analysis. *Eur Radiol* 2017 Jul;27(7):2903-2915.

103. Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, Freeman S, Moyle P, **Sala E**, Sayal K, Hosking K, Gounaris I, Jimenez-Linan M, Earl HE, Qian W, Rosenfeld N, Brenton JD. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective analysis. *PLoS Med* 2016 Dec 20;13(12):e1002198. <https://doi.org/10.1371/journal.pmed.1002198>.
104. Vargas HA, Martin-Malburet AG, Takeda T, Corradi RB, Eastham J, Wibmer A, **Sala E**, Zelefsky MJ, Weber WA, Hricak H. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide? *Urol Oncol*. 2016 Nov; 34(11):482.e5-482.e10.
105. Lawrence EM, Warren AY, Priest AN, Barrett T, Goldman D, Andrew Gill, Gnanapragasam VJ, **Sala E***, Gallagher FA*. Evaluating prostate cancer using fractional tissue composition of radical prostatectomy specimens and pre-operative diffusional kurtosis magnetic resonance imaging. *PLoS ONE* 2016 Jul; 11(7): e0159652.
106. Nougaret S, Reinhold C, Lakhman Y, Guiu B, **Sala E**. Response. *Radiology*. 2016;279(1): 327-328.
107. Vargas HA, Hötter AM, Goldman DA, Moskowitz CS, Gondo T, Matsumoto K, Ehdaie B, Woo S, Fine SW, Reuter VE, **Sala E**, Hricak H. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. *Eur Radiol*. 2016 June; 26(6): 1606-1612.
108. Sharma S, Sevak KK, Monette S, Carlin SD, Knight JC, Wuest FR, **Sala E**, Zeglis BM, Lewis JS. Preclinical ⁸⁹Zr-immunoPET of high-grade serous ovarian cancer and lymph node metastasis. *J Nuc Med* 2016 May; 57(5): 771-776.
109. Lakhman Y, Katz SS, Goldman DA, Yakar D, Vargas HA, Sosa R, Micco M, Soslow R, Hricak H, Abu-Rustum NR, **Sala E**. Diagnostic performance of CT for preoperative staging of patients with non-endometrioid carcinomas of the uterine corpus. *Ann Surg Oncol* 2016 Apr; 23(4):1271-78.
110. Robertson NL, Hricak H, Sonoda Y, Sosa R, Benz M, Lyons G, Abu-Rustum N, **Sala E**, Vargas AH. The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer. *Gynecol Oncol* 2016 Mar; 140(3):420 - 424.
111. Hussein YR, Ducie JA, Arnold AG, Kauff ND, Vargas AH, **Sala E**, Levine DA, Soslow R. Invasion patterns of metastatic extrauterine high grade serous carcinoma with BRCA germline mutation and correlation with clinical outcomes. *Am J Surg Pathol* 2016 Mar; 40(3):302-312.
112. Grisham RN, Sylvester B, Won H, Mcdermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolny F, Makker V, **Sala E**, Hyman DM, Socci N, Viale A, Gershenson DM, Farley J, Levine DA, Rosen N, Berger MF, Spriggs D, Aghajanian C, Solit DB, Iyer G. Extreme outlier analysis identifies occult MAP kinase pathway mutations in patients with low-grade serous ovarian cancer. *J Clin Oncol* 2015 Dec 1; 33(34):4099-4105.
113. Barrett T, Priest AN, Lawrence EML, Goldman DA, Warren AY, Gnanapragasam VJ, **Sala E**, Gallagher FA. Ratio of tumor to normal prostate tissue apparent diffusion coefficient as a method for quantifying DWI of the prostate. *Am J Roentgen* 2015 Dec; 205(6):W585–W593.
114. Fehr D, Veeraraghavan H, Wibmer A, Gondo T, Matsumoto K, Vargas HA, **Sala E**, Hricak H, Deasy JO. Automatic classification of prostate cancer Gleason score from multi-parametric Magnetic Resonance Images *PNAS* 2015 Nov; 112(46):E6265-73.
115. Vargas HA, Burger IA, Goldman DA, Micco M, Sosa RE, Weber W, Chi DS, Hricak H, Levine DA, **Sala E**. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. *Eur Radiol*. 2015 Nov; 25(11): 3348-53

116. Lakhman Y, D'Anastasi M, Micco M, Scelzo C, Vargas AH, Nougaret S, Sosa RE, Chi D, Abu-Rustum N, Hricak H, **Sala E**. Second-opinion interpretations of gynecologic oncologic MRI examinations by sub-specialized radiologists influence patient care. *Eur Radiol* 2015 Oct; <https://doi.org/10.1007/s00330-015-4040-5>.
117. Wibmer A, Hricak H, Gondo T, Matsumoto K, Veeraraghavan H, Fehr D, Zheng J, Moskowitz C, Fine S, Reuter VE, Eastham J, **Sala E**, Vargas HA. Haralick Texture Analysis of prostate MRI: differentiating normal prostate from clinically significant prostate cancer and associations with cancer aggressiveness. *Eur Radiol* 2015 Oct; 25(10):2840-50.
118. **Sala E**, Micco M, Burger IA, Yakar D, Kollmeier M, Goldman DA, Gonen M, Park KJ, Abu-Rustum NR, Hricak H, Vargas HA. Complementary prognostic value of pelvic MRI and whole-body FDG PET/CT in the pretreatment assessment of patients with cervical cancer. *Int J Gynecol Oncol* 2015 Oct;25(8): 1461–1467.
119. Nougaret S, Reinhold C, Alsharif SS, Addley H, Arceneau J, Molinari N, Guiu B, **Sala E**. Endometrial Cancer: Combined MR volumetry and diffusion-weighted imaging for assessment of myometrial and lymphovascular invasion and tumor grade. *Radiology*. 2015 Sep; 276(3):797-808.
120. Burger IA, Goldman DA, Vargas AH, Kattan MW, Yu C, Kou L, Andikyan V, Chi DS, Hricak HH, **Sala E**. Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer. *Gynecol Oncol*. 2015 Sep;138(3):554-9.
121. Lakhman Y, Yakar D, Goldman DA, Katz SS, Vargas HA, Micco M, Zheng J, Moskowitz CS, Soslow R, Hricak H, Abu-Rustum NR, **Sala E**. Preoperative CT-based nomogram for predicting overall survival in women with non-endometrioid carcinomas of the uterine corpus. *Abdominal Imaging* 2015 Aug; 40(6):1761-8.
122. Wibmer A, Vargas HA, Donahue T, Zheng J, Moskowitz C, Eastham J, **Sala E**, Hricak H. Diagnosis of Extracapsular Extension of Prostate Cancer on Prostate MRI: Impact of Second-Opinion Readings by Sub-Specialized Genitourinary Oncologic Radiologists. *AJR Am J Roentgenol*. 2015 Jul; 205(1):W73-8.
123. Vargas HA, Micco M, Hong S, Goldman DA, Dao, F, Weigelt B, Soslow RA, Hricak H, Levine DA, **Sala E**. Association between morphologic computed tomography imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: A Hypothesis Generating Study. *Radiology*. 2015 Mar; 274(3):742-51.
124. Schwarz RF, Ng CKY, Cooke SL, Newman S, Temple J, Piskorz AM, Gale D, Sayal K, Murtaza M, Baldwin PJ, Rosenfeld N, Earl HE, **Sala E**, Jimenez-Linan M, Parkinson CA, Markowitz F, Brenton JD. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic reconstruction. *PLoS Med*. 2015 Feb 24; 12(2).
125. Di Paolo PL, Vargas HA, Karlo KA, Lakhman Y, Zheng J, Moskowitz CS, Al-Ahmadie HA, **Sala E**, Bochner BH, Hricak H. Intra-diverticular bladder cancer: CT imaging features and their association with clinical outcomes. *Clinical Imaging* 2015 Jan/Feb; 39(1):94-98.
126. Gondo T, Hricak H, **Sala E**, Zheng J, Moskowitz CS, Bernstein M, Eastham JA, Vargas HA. Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer. *Eur Rad* 2014 Dec; 24 (12):3161-3170.
127. Vargas HA, Donati OF, Wibmer A, Goldman DA, Mulhall JP, **Sala E**, Hricak H. Association between penile dynamic contrast-enhanced MRI derived quantitative parameters and self-reported sexual function in patients with newly diagnosed prostate cancer. *J Sex Med* 2014 Oct;11(10):2581-8.
128. Lawrence EM, Gallagher FA, Barrett T, Warren AY, Priest AN, Goldman D, **Sala E***, Gnanapragasam VJ*. Pre-operative 3-tesla diffusion weighted MRI for the qualitative and quantitative assessment of extracapsular extension in patients with intermediate or high-risk prostate cancer. *Am J Roentgen* 2014 Sep;203(3):W280-6.

129. Grisham RN, Iyer G, **Sala E**, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. *Int J Gynecol Cancer* 2014 Jul;24(6):1010-4.
130. Miccò M, Vargas HA, Burger IA, Kollmeier, MA, Goldman DA, Park KJ, Abu-Rustum NR, Hricak H, **Sala E**. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. *Eur J Radiol* 2014 Jul;83(7):1169-76.
131. Lawrence EM, Tang SYW, Barrett T, Koo B, Goldman DA, Warren AY, Axell R, Doble A, Gallagher FA, Gnanapragasam VJ, Kastner C, **Sala E**. Prostate cancer: Performance characteristics of combined T2W and DW-MRI scoring in the setting of template transperineal rebiopsy using MR-TRUS fusion. *Eur Radiol* 2014 Jul;24(7):1497-505.
132. Rockall AG, Avril NE, Lam R, Iannone R, David Mozley DP, Parkinson C, Bergstrom D, **Sala E**, Sarker S, McNeish IA, Brenton JD. Repeatability of quantitative FDG-PET/CT and contrast enhanced CT in recurrent ovarian carcinoma: test retest measurements for tumor FDG uptake, diameter and volume. *Clin Cancer Res* 2014 May; 20(10); 1–10.
133. Milgrom SA, Vargas HA, **Sala E**, Kelvin JF, Hricak H, Goodman KA. Acute effects of pelvic irradiation on the adults uterus revealed by dynamic contrast-enhanced MRI. *Br J Radiol*. 2013 Nov; 86: 1031.
134. Vargas HA, Burger IA, Donati OF, Andikyan V, Lakhman Y, Goldman, Schoder H, Chi DS, **Sala E**, Hricak H. MRI/PET provides a roadmap for surgical planning and serves as a predictive biomarker in patients with recurrent gynecological cancers undergoing pelvic exenteration. *Int J Gynecol Cancer*. 2013 Oct, 23(8):1512-1519.
135. Donati OF, Lakhman Y, **Sala E**, Burger IA, Vargas HA, Goldman D, Andikyan V, Park, KJ, Chi DS, Hricak H. Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration. *Eur Radiol*. 2013 Oct, 23(10):2906-2915
136. Burger IA, Vargas HA, Donati OF, Andikyan V, **Sala E**, Gonen M, Goldman D, Chi DS, Schoder H, Hricak H. The Value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. *Gynecol Oncol* 2013 Jun;129(3):586-592.
137. Annamalai AK, Cluroe AD, **Sala E**, Park SM, MacDougall J, Hughes IA, Simpson HL. Puberty reveals a familial disorder of sex development. *Endocrine*. 2012 Oct; 42(2):453-5.
138. Peters NHGM, Patterson AJ, Horan G, Gregory D, and **Sala E**. Assessment of ovarian movement on consecutive pelvic MRI examinations in patients with gynaecologic malignancies: what is the planning organ at risk volume for radiotherapy. *Br J Radiol*. 2012 Oct; 85(1018):1407-14.
139. Griffin N, Addley H, **Sala E**, Shaw A, Grant LA, Eldaly H, Davies SE, Prevost T, Alexander GJ, Lomas DJ. Vascular invasion in hepatocellular carcinoma: Is there a correlation with MRI. *Br J Radiol*. 2012 Jun; 85(1014):736-44.
140. **Sala E**, Kataoka MY, Priest AN, Gill AB, McClean MA, Joubert I, Graves MJ, Crawford R, Jimenez-Linan M, Earl H, Hodgkin C, Griffiths JR, Lomas DJ, Brenton JD. Advanced Ovarian Cancer: Multiparametric MR imaging demonstrates response- and metastasis-specific effects. *Radiology* 2012 Apr; 263(1):149-159.
141. Barrett T, Gill AB, Kataoka MY, Priest AN, Joubert I, McLean MA, Graves MJ, Stearn S, Lomas DJ, Griffiths JR, Neal D, Gnanapragasam VJ, **Sala E**. DCE-MRI and DW-MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A Feasibility study. *Magn Res Med* 2012 Mar; 67(3):778-785.
142. Beddy P, Moyle P, Kataoka MY, Yamamoto AK, Joubert I, Lomas DJ, Crawford R, **Sala E**. Evaluation of depth of myometrial invasion and overall staging in endometrial cancer: comparison of diffusion-weighted and dynamic contrast-enhanced MR imaging. *Radiology*. 2012 Feb; 262(2):530-7.

143. Anandappa G, **Sala E**, Cheow HK, Bird NJ, Shaw A, Priest AN, Gill A, Fryer T, Hong YT, Smith R, Backen A, Whitcher B, Jonson A, Richards D, Cookson L, Lee WMF, Dive C, Fife KM, Jodrell DI, Eisen T. Pharmacodynamic study of antiangiogenic therapy in patients with renal cell carcinoma. *Journal of Clinical Oncology* 29, no. 15_suppl - published online before print. PMID: 28022980
144. Mironov O, Mironov S, **Sala E**, Pannu H, Zheng J, Moskowitz CS, Hricak H, Chi DS. Thoracic metastases in advanced cancer: comparison between computed tomography and video-assisted thoracic surgery. *Journal of Gynecologic Oncology* 2011 Dec;22(4):260-8.
145. Gourtsoyianni S, Hudolin T, **Sala E**, Goldman D, Bochner BH, Hricak H. MRI at the completion of chemoradiotherapy can accurately evaluate the extent of disease in women with advanced urethral carcinoma undergoing anterior pelvic exenteration. *Clin Radiol* 2011 Nov; 66(11):1072-8.
146. Neale H, Housden R, Crawford R, Treece G, **Sala E**, Gee A, Prager R. A pilot study using transvaginal real-time ultrasound elastography to evaluate the postmenopausal endometrium. *Ultrasound Obstet Gynecol.* 2011 Aug; 38(2):235-6.
147. McLean MA, Barrett T, Gnanapragasam VJ, Priest AN, Joubert I, Lomas DJ, Neal DE, Griffiths JR, **Sala E**. Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla. *Magn Reson Med.* 2011 Apr; 65(4):914-9.
148. **Sala E**, Mannelli L, Yamamoto K, Griffin M, Griffin N, Grant L, Parker R, Crawford R. The value of postoperative/pre-adjuvant chemotherapy computed tomography in the management of patients with ovarian cancer. *Int J Gynecol Cancer* 2011 Feb; 21(2): 296-301.
149. Beddy P, Rangarajan RD, Kataoka M, Moyle P, Graves MJ, **Sala E**. T1-weighted fat-suppressed imaging of the pelvis with a dual-echo Dixon technique: initial clinical experience. *Radiology.* 2011 Feb; 258(2):583-9.
150. Cooke SL, Temple J, MacArthur S, Zahra MA, Tan LT, Crawford RA, Ng CK, Jimenez-Linan M, **Sala E**, Brenton JD. Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer. *Br J Cancer.* 2011 Jan 18; 104(2):361-8.
151. Addley HC, Crawford RAF, Jimenez-Linan M, **Sala E**. Primary neuroendocrine carcinoma of the Bartholin's gland: magnetic resonance imaging findings with pathologic correlation. *Eur J Radiol* 2010 Jul; 75(1):e37-e38.
152. **Sala E**, Kataoka M, Pandit-Taskar N, Ishill N, Mironov S, Mosckowitz CS, Mironov O, Collins MA, Chi DS, Larson S, Hricak H. Recurrent ovarian cancer: contrast-enhanced CT and PET/CT can accurately localize tumor recurrence and to predict patients' survival. *Radiology.* 2010 Oct; 257(1):125-34.
153. Mannelli L, Patterson AJ, Zahra M, Priest AN, Graves MJ, Lomas DJ, Tan LT, Crawford R, Brenton J, **Sala E**. Evaluation of nonenhancing tumor fraction assessed by dynamic contrast-enhanced MRI subtraction as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer. *AJR Am J Roentgenol.* 2010 Aug; 195 (2):524-7.
154. Grant L, Moyle P, Griffin N, Williams M, **Sala E**, Vasconcelos J, Dixon A. Visceral abdominal obesity - is there an increased prevalence in men presenting with testicular teratoma. *Acta Radiol, Acta Radiol.* 2010 Jul; 51 (6):687-92.
155. Priest AN, Gill, AB, Kataoka M, McClean MA, Joubert I, Graves MJ, Griffiths JR, Crawford RA, Earl H, Brenton JD, Lomas DJ, **Sala E**. Dynamic contrast-enhanced MRI in ovarian cancer: initial experience at 3 Tesla in primary and metastatic disease. *Mag Res Med,* 2010 Apr; 63 (4):1044-9.
156. Kataoka MY, **Sala E**, Baldwin P, Reinhold C, Farhadi A, Hudolin T, Hricak H. The accuracy of magnetic resonance imaging in staging of vulvar cancer: a retrospective multi-centre study. *Gynecol Oncol,* 2010 Apr; 117 (1):82-7.

157. **Sala E**, Priest AN, Kataoka M, Graves MJ, McClean MA, Joubert I, Griffiths JR, Crawford RA, Jimenez-Linan M, Earl HM, Brenton JD, Lomas DJ. Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3T: technical development. *Eur Radiol*. 2010 Feb; 20 (2):491-6.
158. **Sala E**, Beadsmoore C, Gibbons D, Shaw A, Gaskarth M, Groot-Wassink T, Watson C, Dixon AK. Unexpected changes in clinical diagnosis: early abdomino-pelvic computed tomography compared with clinical evaluation. *Abdominal Imaging*, 2009 Nov; 34 (6):783-7.
159. McClean MA, Priest AN, Joubert I, Lomas DJ, Kataoka MJ, Earl H, Crawford R, Brenton JD, Griffiths JR, **Sala E**. Metabolic characterisation of primary and metastatic ovarian cancer by ¹H MRS in vivo at 3 Tesla. *Mag Res Med*, 2009 Oct; 62(4):855-61.
160. Zahra MA, Tan LT, Priest AN, Graves MJ, Arends M, Crawford RA, Brenton JD, Lomas DJ, **Sala E**. Semiquantitative and quantitative dynamic contrast enhanced magnetic resonance imaging predicts radiation response in cervix cancer. *Int J Radiat Oncol Biol Phys*. 2009 Jul 1; 74 (3):766-73.
161. Shah AK, **Sala E**, Staiano JJ. If the scan fits — evacuate! *J Plast Reconstr Aesthet Surg* 2009 Apr; 62 (4):554-5.
162. **Sala E**, Crawford R, Senior E, Shaw A, Simcock B, Vrotsou K, Palmer C, Rajan P, Joubert I, Lomas DJ. Added value of dynamic contrast-enhanced magnetic resonance imaging in predicting advanced stage disease in patients with endometrial carcinoma. *Int J Gynecol Cancer*. 2009 Jan; 19(1):141-6.
163. Griffin N, Grant LA, Freeman SJ, Jimenez-Linan M, Berman LH, Earl H, Ahmed AA, Crawford R, Brenton J, **Sala E**. Image guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique? *Eur Radiol*. 2009 Jan; 19 (1):230-5.
164. Soh E, Eleti A, Jimenez-Linan M, Arends MJ, Latimer J, **Sala E**. Magnetic resonance imaging findings of tamoxifen-associated uterine mullerian adenosarcoma. *Acta Radiol* 2008 Sep; 49 (7):848-51.
165. Ringl H, Scherthaner R, **Sala E**, El-Rabadi K, Weber M, Schima W, Herold CJ, Dixon AK. Lossy three-dimensional JPEG2000 compression of abdominal CT images in patients with acute abdominal complaints: effect of compression ratio on diagnostic confidence and accuracy. *Radiology*, 2008 Aug; 248 (2):476-84.
166. Akin O, **Sala E**, Moskowitz CS, Ishill N, Soslow RA, Chi DS, Hricak H. Perihepatic metastases from ovarian cancer: sensitivity and specificity of CT for the detection of metastases with and those without liver parenchymal invasion. *Radiology*. 2008 Aug; 248 (2):511-7.
167. Hugill J, **Sala E**, Hollingsworth KG, Lomas DJ. MR sialography: the effect of a sialogogue and ductal occlusion in volunteers. *Br J Radiol*. 2008 Jul; 81 (967):583-6.
168. Kataoka M, Atkinson C, Warren R, **Sala E**, Day NE, Hingham R, Warsi I, Bingham SA. Mammographic density using two computer-based methods in an Isoflavone trial. *Maturitas*. 2008 Apr 20;59 (4):350-7.
169. Addley H, Grant LA, Crawford R, **Sala E**: Medical image. A prepubescent mass. Swyer syndrome with a bilateral dysgerminoma. *N Z Med J*, 2008 Apr 4; 121 (1271):117-8.
170. Warren R, Thompson D, del Frate C, Cordell M, Highnam R, Tromans C, Warsi I, Ding J, **Sala E**, Estrella F, Solomonides AE, Odeh M, McClatchey R, Bazzochi M, Amendolia SR, Brady M. A comparison of some anthropometric parameters between an Italian and a UK population: "proof of principle" of a European project using MammoGrid. *Clin Radiol*, 2007 Nov; 62 (11):1052-60.
171. **Sala E**, Watson CJ, Beadsmoore C, Groot-Wassink T, Fanshawe TR, Smith JC, Bradley A, Palmer CR, Shaw A, Dixon AK. A randomized, controlled trial of routine early abdominal computed tomography in patients presenting with non-specific acute abdominal pain. *Clin Radiol*. 2007 Oct; 62 (10):961-9.

172. Koo BC, **Sala E**, Hackett GA, Shaw A. A pregnant lady with recurrent vaginal bleeding (2007:3b). Placenta precreta. *Eur Radiol*, 2007 Jun; 17 (6):1647-9.
173. Zahra MA, **Sala E**, Lomas DJ, Crawford RAF, Brenton J, Arends M, Tan LT. The predictive role of functional imaging in cervix cancer. *Clin Oncol*, 2007 Apr;19(3):S51.
174. **Sala E**, Graves MJ, Abubacker Z, Kershaw LE, Black RT, Skinner J, Beavon R, Lomas DJ. High resolution Magnetic Resonance Cholangiography (MRC) with adaptive averaging: diagnostic performance evaluation. *Clin Radiol*, 2006 Sep; 61 (9):766-70.
175. Warren R, Skinner J, **Sala E**, Denton E, Dowsett M, Folkard E, Healey CS, Dunning A, Doody D, Ponder B, Luben RN, Day NE, Easton D. Associations between mammographic density, circulating sex hormones and polymorphisms in sex hormone metabolism genes in post-menopausal women. *Cancer Epidemiol Biomarkers Prev*, 2006 Aug; 15 (8):1502-8.
176. Kataoka M, Warren R, Luben R, Camus J, Denton E, **Sala E**, Day N, Khaw KT. How predictive is breast arterial calcification of cardiovascular disease and risk factors when found at screening mammography? *AJR Am J Roentgenol*. 2006 Jul; 187 (1):73-80.
177. Akin O, **Sala E**, Moskowitz C, Eisenberg H, Kuroiwa K, Ishill N, Scardino P, Hricak H. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. *Radiology*. 2006 Jun; 239 (3):784-92.
178. Graves MJ, Kershaw LE, Black RT, **Sala E**, Skinner J, Lomas DJ. Interactive magnetic resonance cholangiopancreatography (MRC) with adaptive averaging. *J Magn Reson Imaging*. 2006 Apr; 23 (4):529-33.
179. **Sala E**, Akin O, Moskowitz C, Eisenberg H, Kuroiwa K, Ishill NM, Rajashankar B, Scardino PT, Hricak H. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. *Radiology*. 2006 Mar; 238 (3):929-37.
180. Gallagher FA, Gopalan D, **Sala E**. Ankylosing spondylitis: an unusual cause for complete heart block (2005:10b). *Eur Radiol*, 2006 Jan (1); 16:244-6.
181. **Sala E**, Eberhardt SC, Akin O, Moskowitz CS, Onyebuchi CN, Kuroiwa K, Ishill N, Zelefsky MJ, Eastham JA, Hricak H. Endorectal MR Imaging prior to salvage prostatectomy: tumor localization and staging. *Radiology*, 2006 Jan;238 (1):176-83.
182. Beadsmoore CJ, Cheow HK, **Sala E**, Lomas DJ, Gibbs P, Save V, Balan KK, Alison MED. Hepatocellular carcinoma tumour thrombus in a re-canalised paraumbilical vein: detection by ¹⁸F-FDG PET. *Br J Radiol*, 2005 Sep; 78(933):841-4.
183. Lomas DJ, Habib S, Joubert I, **Sala E**, Graves, MJ. CO₂ as a distending medium for gastric and small bowel MRI. *Eur Radiol*, 2005 Apr; 15 (4):672-6.
184. Jardine VL, **Sala E**, Lomas DJ. MR Colonography: Baseline appearance of the unprepared rectosigmoid. *Br J Radiol*, 2005 Mar; 78 (927):202-6.
185. Atkinson C, Warren RM, **Sala E**, Dowsett M, Dunning AM, Healey CS, Runswick S, Day NE, Bingham SA. Red-clover-derived isoflavones and mammographic breast density: a double blind, randomized, placebo-controlled trial. *Breast Cancer Res*, 2004; 6 (3):R170-9.
186. **Sala E**, Coulden RA. Incidental bronchogenic cyst detected on ¹⁸F-FDG positron emission tomography. *Clin Nucl Med*, 2004 Aug; 29:494-495.
187. **Sala E**, Coulden RA, Goddard M. Incidental detection of an autonomous nodule in retrosternal goitre on F-18 FDG positron emission tomography. *Clin Nucl Med*, 2004 Nov; 29 (11):732-3.

188. U-King-Im JM, Trivedi RA, **Sala E**, Graves MJ, Gaskarth M, Higgins NJ, Cross JC, Hollingworth W, Coulden RA, Kirkpatrick PJ, Antoun NM, Gillard JH. Evaluation of carotid stenosis with axial high-resolution black-blood MR imaging. *Eur Radiol*, 2004 Jul;14 (7):1154-61.
189. Bjurstam N, Björnelid I, Warwick J, **Sala E**, Duffy SW, Nyström L, Walker N, Cahlin E, Eriksson O, Hafström L, Lingaas H, Mattsson J, Persson S, Rudenstam CM, Salander H, Sävje-Söderbergh J, Wahlin T. The Göteborg breast screening trial. *Cancer*, 2003 May 15;97 (10):2387-96.
190. Bjurstam N, Björnelid I, Warwick J, **Sala E**, Duffy SW, Nyström L, Walker N, Cahlin E, Eriksson O, Hafström L, Lingaas H, Mattsson J, Persson S, Rudenstam CM, Salander H, Sävje-Söderbergh J, Wahlin T. Age-specific effects of mammography screening: the randomised breast screening trial in Göteborg. *Am J Onc Rev*, 2003; 2:435-442.
191. Harrison DA, Duffy SW, **Sala E**, Warren RM, Couteau E, Day NE. Deterministic models for breast cancer progression: Application to the association between mammographic parenchymal patterns and histological grade of breast cancers. *J Clin Epidemiol*, 2002 Nov; 55:1113-8.
192. **Sala E**, Warren R, McCann J, Duffy S, Luben R, Day N. Mammographic parenchymal patterns and breast cancer natural history: a case-control study. *Acta Oncol* 2001 Jul;40 (4):461-5.
193. Couto E, Harrison D, Duffy S, Myles J, **Sala E**, Warren R, Day N, Luben R, Chen H. Estimation of disease progression parameters from case-control data: application to mammographic patterns and breast cancer natural history. *J Epidemiol Biostat* 2001 Jan;6 (2):235-42.
194. **Sala E**, Solomon L, Warren R, McCann J, Duffy S, Luben R, Day N. Size, node status and grade of breast tumours: association with mammographic parenchymal patterns. *Eur Radiol* 2000 Jan;10 (1):157-61.
195. **Sala E**, Warren R, McCann J, Duffy S, Luben R, Day N. Smoking and high-risk mammographic parenchymal patterns: a case control study. *Breast Cancer Res*. 2000;2(1):59-63.
196. **Sala E**, Warren R, McCann J, Duffy S, Luben R, Day N. High-risk mammographic parenchymal patterns, hormone replacement therapy and other risk factors: a case-control study. *Int J Epidemiol* 2000 Aug;29 (4):629-36.
197. **Sala E**, Warren R, Duffy S, Welch A, Luben R, Day N. High-risk mammographic parenchymal patterns and diet: a case-control study. *Br J Cancer* 2000 Jul; 83 (1):121-6.
198. **Sala E**, Warren R, McCann J, Duffy S, Luben R, Day N. High-risk mammographic parenchymal patterns and anthropometric measures: a case-control study. *Br J Cancer* 1999; Dec 81:1257-61.
199. **Sala E**, Warren RML, Day NE. Mammographic parenchymal patterns and breast cancer risk by mode of detection: implications for the breast screening programme. *Eur Radiol* 1999; 9(S1): S10.
200. **Sala E**, Warren R, McCann J, Duffy S, Day N, and Luben R. Mammographic parenchymal patterns and mode of detection: implications for the breast screening programme. *J Med Screen* 1998 Dec;5 (4):207-12.
201. Selenica G, Duffy SW, Sallaku A, **Sala E**. Preoperative therapy in locally advanced rectal cancer. *Journal of BUON* 1998; 4:315-9.
202. **Sala E**, Olsen J. Thyroid cancer in age group 0-19: Time trends and temporal changes in radioactive fallout. *Eur J Cancer* 1993; 29(10):1443-5

REVIEWS, BOOKS AND BOOK CHAPTERS

Reviews

1. Clauser P, Dolcianni M, Grassi F, D'Amario A, Persiani S, Celli V, Oliva E, Fragomeni SM, Garganese G, **Sala E**, Gui B. The role of magnetic resonance imaging in the rare pathologies of the vulva. *Eur J Radiol*. 20 Jan 2025. doi:10.1016/j.ejrad.2025.111926. Online ahead of print.
2. Rizzo S, Avesani G, Panico C, Manganaro L, Gui B, Lakhman J, Andrieu PC, Bharwani N, Rockall A, Thomassin-Naggara I, Cunha TM, **Sala E**, Forstner R, Nougaret S. Ovarian cancer staging and follow-up: updated guidelines from the European Society of Urogenital Radiology female pelvic imaging working group. *Eur Radiol*. 11 Jan 2025. doi: 10.1007/s00330-024-11300-7. Online ahead of print.
3. De-Giorgio F, Benedetti B, Mancino M, **Sala E**, Pascali VL. The need for balancing 'black box' systems and explainable artificial intelligence: A necessary implementation in radiology. *Eur J Radiol*. 2025 Mar 2. doi: 10.1016/j.ejrad.2025.112014. Online ahead of print.
4. De-Giorgio F, Benedetti B, Mancino M, **Sala E**, Pascali VL. Post-Mortem imaging biobanks: Building data for reproducibility, standardization, and AI integration. *Eur J Radiol*. 2025 Mar 2. doi: 10.1016/j.ejrad.2025.112011. Online ahead of print.
5. Leithner D, Neri E, D'Anastasi M, Schlemmer HP, Winkelmann M, Kunz WG, Cyran CC, Cioni D, **Sala E**, Mayerhoefer ME. ESR Essentials: Imaging of lymphoma – practice recommendations by the European Society of Oncologic Imaging. *Eur Radiol*. 2025 Jan 2. doi:10.1007/s00330-024-11213-5. Online ahead of print.
6. Lococo F, Ghaly G, Flamini S, Campanella A, Chiappetta M, Bria E, Vita E, Tortora G, Evangelista J, Sassorossi C, Congedo MT, Valentini V, **Sala E**, Cesario A, Margaritora S, Boldrini L, Mohammed A. Artificial intelligence applications in personalizing lung cancer management: state of the art and future perspectives. *J. Thorac. Dis*. 2024 Oct 30. doi:10.21037/jtd-24-244.
7. Fionda B, Placidi E, de Ridder M, Strigari L, Patarnello S, Tanderup K, Hannoun-Levi JM, Siebert FA, Boldrini L, Gambacorta MA, De Spirito M, **Sala E**, Tagliaferri L. Artificial intelligence in interventional radiotherapy (brachytherapy): Enhancing patient-centered care and addressing patients' needs. 2024 Sep 25. doi: 10.1016/j.ctro.2024.100865.
8. Fionda B, Placidi E, de Ridder M, Strigari L, Patarnello S, Tanderup K, Hannoun-Levi JM, Siebert FA, Boldrini L, Gambacorta MA, De Spirito M, **Sala E**, Tagliaferri L. Artificial intelligence in interventional radiotherapy (brachytherapy): Enhancing patient-centered care and addressing patients' needs. 2024 Sep 22. Special Issue of Brachytherapy. doi: 10.1016/j.ctro.2024.100865.
9. Zormpas-Petridis K, Vagni M, Mancino M, **Sala E**. Editorial Comment: Integrating Morphomics in Clinical Practice for Personalized Medicine: A Paradigm Shift Toward Holistic Care. *Canadian Association of Radiologists Journal*. 2024;75(4):706-707. doi:10.1177/08465371241264248.
10. Avesani G, Bonatti M, Venkatesan AM, Nougaret S, **Sala E**. RadioGraphics Update: 2023 FIGO Staging System for Endometrial Cancer. *Radiographics*. 2024 Jul;44(7):e240084. doi: 10.1148/rg.240084.
11. Avesani G, Panico C, Nougaret S, Woitek R, Gui B, **Sala E**. ESR Essentials: characterisation and staging of adnexal masses with MRI and CT-practice recommendations by ESUR. *Eur Radiol*. 2024 Jun 7. doi: 10.1007/s00330-024-10817-1.
12. Russo L, Charles-Davies D, Bottazzi S, **Sala E**, Boldrini L. Radiomics for clinical decision support in radiation oncology. *Clin Oncol (R Coll Radiol)*. 2024 Mar 15. doi: 10.1016/j.clon.2024.03.003. Online ahead of print.
13. Perez-Lopez R, Liger Hernandez M, Gielen B, Navarro V, Cresta P, Prior O, Dienstmann R, Nuciforo P, Treschi S, Beets-Tan R, **Sala E**, Garralda E. A whirl of radiomics-based biomarkers in cancer immunotherapy, why is large scale validation still lacking?. *NPJ Precision Oncology*. 2024, Vol.8(1). **DOI:** 10.1038/s41698-024-00534-9
14. Leithner D, **Sala E**, Neri E, Schlemmer H-P, D'Anastasi M, Weber M, Avesani G, Caglic I, Caruso D, Gabelloni M, Goh V, Granata V, Kunz WG, Nougaret S, Russo L, Woitek R, Marius E. Mayerhoefer ME.

Perceptions of radiologists on structured reporting for cancer imaging – a survey by the European Society of Oncologic Imaging (ESOI). *Eur Radiol*. 2024 Jan 11. doi: 10.1007/s00330-023-10397-6.

15. Russo L, Bottazzi S, **Sala E**. Artificial intelligence in female pelvic oncology: tailoring applications to clinical needs. *Eur Radiol*. 2023 Nov 22. doi: 10.1007/s00330-023-10455-z. Online ahead of print.
16. Oprea-Lager DE, MacLennan S, Bjartell A, Briganti A, A Burger I, de Jong I, De Santis M, Eberlein U, Emmett L, Fizazi K, Gillessen S, Herrmann K, Heskamp S, Iagaru A, Jereczek-Fossa BA, Kunikowska J, Lam M, Nanni C, O'Sullivan JM, Panebianco V, **Sala E**, Sathekge M, Sosnowski R, Tilki D, Tombal B, Treglia G, Tunariu N, Walz J, Yakar D, Dierckx R, Sartor R, Fanti S. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer. *Eur Urol*, 2024 Jan;85(1):49-60. doi: 10.1016/j.eururo.2023.09.003. Epub 2023 Sep 22.
17. Hatamikia S , Nougaret S , Panico C, Avesani G, Nero C, Boldrini L , **Sala E**, Woitek R. Ovarian cancer beyond imaging: integration of AI and multiomics biomarkers. *Eur Radiol Exp*. Published online 2023 Sept 13; 7:50. doi:10.1186/s41747-023-00364-7.
18. Iezzi R, Posa A, Contegiacomo A, Lee IJ, Bale R, Tanzilli A, Tenore L, Giuliani F, Gasbarrini A, Goldberg SN, Jakobs T, Pompili M, Bargellini I, **Sala E**, Kim HC. Early-Stage HCC Percutaneous Locoregional Management: East versus West Perspectives. *Cancers (Basel)*. 2023 Aug 6, 15 (15) 3988. Doi: 10.3390/cancers15153988
19. Avesani G, Perazzolo A, Amerighi A, Celli V, Panico C, **Sala E**, Gui B. The Utility of Contrast-Enhanced Magnetic Resonance Imaging in Uterine Cervical Cancer: A Systematic Review. *Life*. 2023 June 12. 13 (6) 1368. doi: 10.3390/life13061368.
20. Posa A, Contegiacomo A, Ponziani FR, Punzi E, Mazza G, Scrofani A, Pompili M, Goldberg SN, Natale L, Gasbarrini A, **Sala E**, Iezzi R. Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends. *Int. J. Mol. Sci.* Apr 2023 16; 24 (8) 7344. doi: [10.3390/ijms24087344](https://doi.org/10.3390/ijms24087344).
21. Panico C, Avesani G, Zormpas-Petridis K, Rundo L, Nero C, **Sala E**. Radiomics and Radiogenomics of Ovarian Cancer Implications for Treatment Monitoring and Clinical Management. *Radiol Clin North Am*. 2023 March 31; 71 (4) 749-760. doi: 10.1016/j.rcl.2023.02.006.
22. Posa A, Tenore L, Barbieri P, Mazza G, **Sala E**, Iezzi R. The Role of the Transjugular Intrahepatic Porto-Systemic Shunt in an Emergency Setting. *Life; Special Issue Physiology and Pathology: Feature Review Papers*. 2023 March 24; 13 (4) 868. doi: 10.3390/life13040868.
23. Koh DM, Papanikolaou N, Bick U, Illing R, E Kahn Jr C, Kalpathi-Cramer J, Matos C, Martí-Bonmatí L, Miles A, Ki Mun S, Napel S, Rockall A, **Sala E**, Strickland N, Prior F. Artificial intelligence and machine learning in cancer imaging. *Commun Med (Lond)*. 2022 Oct 27; 2:133. doi: 10.1038/s43856-022-00199-0
24. Funingana I.G., Piyatissa P., Reinius M., McCague C., Basu B., and **Sala E**. Radiomic and Volumetric Measurements as Clinical Trial Endpoints—A Comprehensive Review. *Cancer*, 17 October 2022 <https://doi.org/10.3390/cancers14205076>
25. McCague C, Ramlee R, Reinius M, Selby I, Hulse D, Piyatissa P, Bura V, Crispin-Ortuzar M, **Sala E**, Woitek R. Introduction to radiomics for a clinical audience. *Clinical Radiology* 31 August 2022. DOI: [10.1016/j.crad.2022.08.149](https://doi.org/10.1016/j.crad.2022.08.149)
26. Bonanno N, Cioni D, Caruso D, Cyran CC, Dinkel J, Fournier L, Gourtsoyianni S, Hoffmann RT, Laghi A, Martincich L, Mayerhoefer ME, Zamboni GA, **Sala E**, Schlemmer HP, Neri E, D'Anastasi M. "Attitudes and perceptions of radiologists towards online (virtual) oncologic multidisciplinary team meetings during the COVID-19 pandemic—a survey of the European Society of Oncologic Imaging (ESOI)." *European Radiology*. 2022 Aug 20:1-11. doi: 10.1007/s00330-022-09083-w.

27. Ramlee S, Hulse D, Bernatowicz K , Raquel Pérez-López R, **Sala E** and Aloj L. Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study. *Cancers* 2022, 14, 3656. <https://doi.org/10.3390/cancers14153656>.
28. Stewart GD, Klatte T, Cosmai L, Bex A, Lamb BW, Moch H, **Sala E**, Siva S, Porta C, Gallieni M. The multispeciality approach to the management of localised kidney cancer. *The Lancet* 2022, [https://doi.org/10.1016/S0140-6736\(22\)01059-5](https://doi.org/10.1016/S0140-6736(22)01059-5) 1
29. Nougaret S, Lakhman Y, Gourgou S , Kubik-Huch R, Derchi L, **Sala E**, Forstner R and the European Society of Radiology (ESR) and the European Society of Urogenital Radiology (ESUR) MRI in female pelvis: an ESUR/ESR survey. *Insights into Imaging* 2022, <https://doi.org/10.1186/s13244-021-01152-w>.
30. Sushentsev N, Moreira Da Silva N, Yeung M, Barrett T, **Sala E**, Roberts M, Rundo L. Comparative Performance of Fully-Automated and Semi-Automated Artificial Intelligence Methods for the Detection of Clinically Significant Prostate Cancer on MRI: a Systematic Review. *Insights into Imaging* 2022, <https://doi.org/10.1186/s13244-022-01199-3>.
31. Doran SJ, Al Sa'd M, Petts JA, Darcy J, Alpert K, Cho W, Escudero Sanchez L, Alle S, El Harouni A, Genereaux B, Ziegler E, Harris GJ, Aboagye EO, **Sala E**, Koh D-M, Marcus D. Integrating the OHIF Viewer into XNAT: Achievements, Challenges and Prospects for Quantitative Imaging Studies. *Tomography* 2022, 8(1), 497-512; <https://doi.org/10.3390/tomography8010040>.
32. Sushentsev N, Moreira Da Silva N, Yeung M, Barrett T, **Sala E**, Roberts M, Rundo L. Comparative performance of fully-automated and semi-automated artificial intelligence methods for the detection of clinically significant prostate cancer on MRI: a systematic review. *Insights Imaging*. 2022 March 28; 13 (1) 59.doi: 10.1186/s13244-022-01199-3
33. Shinagare AB, Sadowski EA, Park H, Brook O, Forstner R, Wallace S, Horowitz JM, Horowitz N, Javitt M, Jha P, Kido A, Lakhman Y, Lee S, Manganaro L, Maturen KE, Stephanie S, Poder L, Rauch GM, Reinhold C, **Sala E**, Thomassin-Naggara I, Vargas A, Venkatesan A, Nikolic O, Rockall AG. Ovarian Cancer Reporting Lexicon for Computed Tomography (CT) and Magnetic Resonance (MR) Imaging Developed by the SAR Uterine and Ovarian Cancer Diseased Focused Panel and the ESUR Female Pelvic Imaging Working Group. *European Radiology* 2021, <https://doi.org/10.1007/s00330-021-08390-y>.
34. McAteer MA, O'Connor JPB, Koh DM, Leung HY, Doran SJ, Jauregui-Osoro M, Muirhead N, Brew-Graves C, Plummer ER, **Sala E**, Ng T, Aboagye EO, Higgins GS, Punwani S. Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers. *Br J Cancer* 2021, <https://doi.org/10.1038/s41416-021-01497-5>.
35. Pintican R, Bura V, Zerunian M, Smith J, Addley H, Freeman S, Caruso D, Laghi A, **Sala E**, Jimenez-Linan M. MRI of the endometrium - from normal appearances to rare pathology. *Br J Radiol* 2021; DOI: 10.1259/bjr.20201347
36. Petralia G, Koh DM, Attariwala R, Busch JJ, Eeles R, Karow D, Lo GG, Messiou C, **Sala E**, Vargas HA, Zugni F, Padhani AR. Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. *Radiology*, 2021. <https://doi.org/10.1148/radiol.2021201740>.
37. Crispin-Ortuzar M, **Sala E**. Precision radiogenomics: fusion biopsies to target tumour habitats in vivo. *Br J Cancer*, 2021. <https://doi.org/10.1038/s41416-021-01381-2>.
38. Driggs D, Selby I, Roberts M, Gkrania-Klotsas E, Rudd JHF, Guang Y, Babar J, Schönlieb CB, **Sala E**. Machine learning for COVID-19 diagnosis and prognostication: lessons for amplifying the signal whilst reducing the noise. *Radiology: Artificial Intelligence*, 2021. <https://doi.org/10.1148/ryai.2021210011>.
39. Roberts M, Driggs D, Thorpe M, Gilbey J, Yeung M, Ursprung S, Aviles-Rivero AI, Etmann C, McCague C, Beer L, Weir-McCall JR, Zhongzhao T, Gkrania-Klotsas E, Rudd JHF*, **Sala E***, Schönlieb CB*. Common pitfalls and recommendations for using machine learning to detect and prognosticate for COVID-19 using chest radiographs and CT scans. *Nature Machine Intelligence*, 2021: 3, 199–217 (2021). <https://doi.org/10.1038/s42256-021-00307-0>.

40. Manganaro L, Lakhman Y, Bharwani N, Gui B, Gigli S, Vinci V, Rizzo S, Kiddo A, Cunha TM, **Sala E**, Rockall A, Forstner R, Nougaret S. Staging, recurrence and follow-up of uterine cervical cancer using MRI: Updated Guidelines of the European Society of Urogenital Radiology after revised FIGO staging 2018. *Eur Radiol*, 2021. <https://doi.org/10.1007/s00330-020-07632-9>.
41. **Sala E**, Ursprung S. Artificial intelligence in radiology – the computer’s helping hand needs guidance. *Radiology: AI*, 2020, <https://doi.org/10.1148/ryai.2020200207>.
42. Martin-Gonzales P, Crispin-Ortuzar M, Rundo L, Delgado-Ortet M, Reinus M, Beer L, Woitek R, Ursprung S, Addley H, Brenton JD, Markowitz F, **Sala E**. Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer. *Insights into Imaging*, 2020, <https://doi.org/10.1186/s13244-020-00895-2>.
43. Aloj A, Attili A, Lau D, Caraco C, Lechermann L, Mendichovszky I, Harper I, Cheow H, Casey RT, **Sala E**, Gilbert FJ, Gallagher FA. The emerging role of cell surface receptor and protein binding radiopharmaceuticals in cancer diagnostics and therapy. *Nuclear Medicine and Biology*, 2020, <https://doi.org/10.1016/j.nucmedbio.2020.06.005>.
44. Rundo L, Pirrone R, Vitabile S, **Sala E**, Gambino O. Recent advances of HCI in decision-making tasks for optimized clinical workflows and precision medicine. *Journal of Biomedical Informatics*, 2020, 108:103479 DOI: 10.1016/j.jbi.2020.103479
45. Caglic I, Panebianco V, Vargas AH, Bura V, Woo S, Pecoraro M, Cipollari S, **Sala E**, Barrett T. MRI of bladder cancer - local and nodal staging. *JMRI* 2020; <https://doi.org/10.1002/jmri.27090>
46. Lapa P, Castelli M, Gonçalves, **Sala E**, Rundo L. A Hybrid end-to-end approach integrating conditional random fields into CNNs for prostate cancer detection on MRI. *Appl. Sci.* 2020, 10, 338; <https://doi.org/10.3390/app10010338>
47. Rundo L, Tangherloni A, Galimberti S, Cazzaniga P, Woitek R, **Sala E**, Nobile MS, Mauri G. HaraliCU: GPU-Powered Haralick feature extraction on medical images exploiting the full dynamics of gray-scale levels. *Parallel Computing Technologies; Lecture Notes in Computer Science* 2019; 11657:304-8.
48. Nougaret S, Nikolovski I, Paroder V, Vargas HA, **Sala E**, Carrere S, Tetreau R, Hoeffel C, Forstner R, Lakhman Y. MRI of tumors and tumor mimics in the female pelvis: anatomic pelvic space-based approach. *RadioGraphics* 2019 39:4, 1205-29.
49. Nougaret S, Tibermacine H, Tardieu M, **Sala E**. Radiomics: an introductory guide to what it may foretell. *Curr Oncol Rep* 2019:21:70.
50. Garcia-Figueiras R, Baleato-Gonzales S, Padhani AR, Luna-Alcala A, Valejo-Casas JA, **Sala E**, Villanova JC, Koh D-M, Herranz-Carero M, Vargas AH. How clinical imaging can assess cancer biology. *Insights into imaging*, 2019 Mar 4;10(1):28. doi: 10.1186/s13244-019-0703-0.
51. De Sousa C, Rosenkrantz A, Taouli B, **Sala E**, Saini S, Pedrosa I, Wang Z, Sahani D. Abbreviated abdomen MRI protocols. *Radiographics* 2019 May-Jun;39(3):744-58. doi: 10.1148/rg.2019180123.
52. Nougaret S, Horta M, **Sala E**, Lakhman Y, Thomassin-Naggara I, Kido A, Masselli G, Bharwani N, Sadowski E, Ertmer A, Milagros Otero-Garcia M, Rahel Kubik-Huch R, Cunha TM, Rockall A, Forstner R. Endometrial Cancer MRI staging: updated guidelines of the European society of urogenital radiology. *Eur Radiol* 2019; 29(2):792–805.
53. **Sala E**, Freeman SJ. Editorial Comment: structured reporting of pelvic MRI leads to better treatment planning of uterine leiomyomas. *Eur Radiol* 2018; 28(7):3007-8.
54. Shaikh F, Franc B, **Sala E**, Awan O, Hendrada K, Halabi S, Mohiuddin S, Malik S, Hadley D, Shrestha R. Translational Radiomics – Defining the strategy pipeline & considerations for application - part II: from Clinical implementation to Enterprise. *J Am Coll Radiol*. 2018;15(3 Pt B):543-9.

55. Shaikh F, Franc B, **Sala E**, Awan O, Hendrada K, Halabi S, Mohiuddin S, Malik S, Hadley D, Shrestha R. Translational Radiomics – Defining the strategy pipeline & considerations for application - part I: from Methodology to Clinical implementation. *J Am Coll Radiol*. 2018;15(3 Pt B):538-42.
56. Pinker K, Shitano F, **Sala E**, Do RK, Young RJ, Wibmer AG, Hricak H, Sutton EJ, Morris EA. Background, current role and potential applications of radiogenomics. *J Mag Res Imag* 2018; 47(3):604-20.
57. McEvoy SH, Nougaret S, Abu-Rustum NR, Vargas AH, Sadowski EA, Menias CO, Shitano F, Fujii S, Sosa, RE, Escalon JG, **Sala E**, Lakhman Y. Fertility-Sparing for young patients with gynecologic cancer: How MRI can guide patient selection prior to conservative management. *Abdom Radiol* 2017; 42(10):2488-512.
58. Nougaret S, Lakhman Y, Vargas HA, Colombo PE, Fujii S, Reinhold C, **Sala E**. From staging to prognostication: achievements and challenges of MR imaging in the assessment of endometrial cancer. *Magn Reson Imaging Clin N Am* 2017; 25(3):611-33.
59. Padhani AR, Lecouvet FE, Tunariu N, Koh D, De Keyser F, Collins DJ, **Sala E**, Fanti S, Vargas HA, Petralia G, Schlemmer HP, Tombal HB, de Bono J. Rationale for modernizing imaging in advanced prostate cancer. *Eur Urol Focus* 2017; 3: 223–39.
60. **Sala E**, Mema E, Himoto Y, Veeraraghavan H, Brenton JD, Snyder A, Weigelt B, Vargas HA. Unraveling tumor heterogeneity using next generation imaging: radiomics, radiogenomics and habitat imaging. *Clin Radiol* 2016; 72 (1): 3-10.
61. Padhani AR, Lecouvet FE, Tunariu N, Koh D, De Keyser F, Collins DJ, **Sala E**, Schlemmer HP, Petralia G, Vargas HA, Fanti S, Tombal HB, de Bono J. Metastasis reporting and data system for prostate cancer: Practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. *Eur Urol* 2017 Jan; 71(1): 81-92.
62. Sharma SK, Nemieboka B, **Sala E**, Lewis JS, Zeglis BM. Focus on MI: Molecular Imaging of Ovarian Cancer. *J Nuc Med* 2016; 57(6): 827-33.
63. Wibmer AG, **Sala E**, Hricak H, Vargas HA. The expanding landscape of diffusion-weighted MRI in prostate cancer. *Abdom Radiol* 2016 May; 41(5): 854-6.
64. Nougaret S, Lakhman Y, Reinhold C, Addley HC, Fujii S, Delhom E, Guiu B, **Sala E**. The Wheel of the Mesentery: Imaging Spectrum of Primary and Secondary Mesenteric Neoplasms-How Can Radiologists Help Plan Treatment. Resident and Fellow Education Feature. *Radiographics*. 2016 Mar/Apr;36(2): 412-3.
65. Cowan RA, O'Cearbhaill RE, Chi DS, Gardner GJ, Levine DA, Long Roche K, Sonoda Y, Zivanovic O, Tew WP, **Sala E**, Lakhman Y, Vargas AH, Sarasohn DM, Mironov S, Abu-Rustum NR. Is it time to centralize ovarian cancer care in the United States. *Obstetrical and gynecological survey* 2016 Feb; 71(2): 80-1.
66. Wibmer AG, Burger IA, **Sala E**, Hricak H, Weber WA, Vargas HA. Molecular imaging of prostate cancer. *Radiographics* 2016 Jan/Feb;36(1):142-61.
67. Benz RM, Vargas HA, **Sala E**. Functional MRI techniques in oncology in the era of personalized medicine. *MRI Clinics North America* 2016 Feb; 24(1):1-10.
68. Nougaret S, **Vargas HA**, Horta M, Lakhman Y, Sala E. Ovarian cancer from anatomy to functional imaging. *Current Radiology Reports* 2015; 3 (11):1-12.
69. Vargas HA, Lawrence EML, Mazaheri Y, **Sala E**. Updates in advanced diffusion-weighted magnetic resonance imaging techniques in the of prostate cancer. *World J Radiol* 2015; 7(8): 184-8,
70. Miccò M, **Sala E**, Lakhman Y, Hricak H, Vargas HA. Imaging features of uncommon gynecological cancers. *Am J Roentgenol* 2015; 205: 1346-59.

71. Lakhman Y, Nougaret S, Miccò M, Scelzo C, Vargas HA, Sosa R, Sutton EJ, Chi DS, Hricak H, **Sala E**. Role of MRI and FDG-PET/CT in the selection and follow-up of patients treated with pelvic exenteration for gynecologic malignancies. *Radiographics* 2015; 35:1294-312.
72. Vargas HA, Grimm I, Donati OF, **Sala E**, Hricak H. Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. *European Radiology* 2015; 25:1294-302.
73. **Sala E**. Obstetrics and Gynaecology Guidelines. Making the best use of a department of clinical radiology. The Royal College of Radiologists, UK 2014.
74. Miccò M, **Sala E**, Lakhman Y, Hricak H, Vargas HA. The role of imaging in the pre-treatment evaluation of common gynecological cancers. *Women's Health*. 2014;10(3):299-321.
75. **Sala E**, Rockall A, Freeman SJ, Mitchel D, Reinhold C. The added role of MRI in treatment stratification of patients with gynecological malignancies: What the radiologist needs to know. *Radiology* 2013; 266:717-40.
76. Vargas AH, Barrett T, **Sala E**. Magnetic Resonance Imaging of Ovarian Masses. *JMRI* 2013; 37:265–81.
77. Nougaret S, Tirumani S, Addley H, Pandey H, **Sala E**, Reinhold C. Pearls and Pitfalls in MRI of Gynecologic Malignancy using DWI. *AJR Am J Roentgenol* 2013; 200:261-278.
78. Nougaret S, Addley HC, Colombo PE, Fujii S, Al Sharif SS, Tirumani SH, Jardon C, **Sala E**, Reinhold C. Ovarian carcinomatosis: how can the radiologist help plan the surgical approach. *Radiographics* 2012; 32(6):1775-800.
79. Freeman SJ, Aly AM, Kataoka MY, Addley HC, Reinhold C. **Sala E**. The revised FIGO staging of uterine malignancies: the implications for MR imaging. *Radiographics* 2012; 32(6):1805-27.
80. Khashper A, Addley HC, Abourokbah N, Nougaret S, **Sala E**, Reinhold C. T2-hypointense adnexal lesions: An imaging algorithm. *Radiographics* 2012; 32:1047-64.
81. DeSouza NM, Kyriazi S, **Sala E**. Diffusion-weighted magnetic resonance imaging in pelvic cancer. *Current Medical Imaging Reviews* 2012 May; 8(2):92-9.
82. Moyle PM, **Sala E**. Magnetic resonance imaging of the cervix, and its relevance to the revised International Federation of Gynecology and Obstetrics (FIGO) staging. *Current Medical Imaging Reviews* 2012 May; 8(2):100-6.
83. Lawrence EM, Priest AN, Gnanapragasam VJ, **Sala E**. The emerging role of Diffusion Weighted MRI in Prostate Cancer Management. *Nat Rev Urol* 2012; 9(2):94-101.
84. Beddy P, O'Neill AC, Yamamoto AK, Addley HC, Reinhold C, **Sala E**. The new FIGO Staging System for endometrial cancer: the implications for magnetic resonance imaging. *Radiographics* 2012; 32:241-54.
85. Beddy P, Rangarajan RD, **Sala E**. Role of MRI in Intracavitary brachytherapy for cervical cancer: What the radiologist needs to know. *AJR Am J Roentgenol*. 2011 Mar; 196(3):W341-7.
86. **Sala E**, Vargas HA, Wassberg C, Kyriazi S, deSouza NM. The role of functional MRI and PET/CT in evaluation of patients with primary and recurrent ovarian cancer. *Imaging in Medicine* 2011; 3:333-43.
87. Balleyguier C, **Sala E**, Kinkel K. Staging uterine cervical cancer with magnetic resonance imaging. *Hosp Imag Radiol Europe* 2011; 6:32-5.
88. Balleyguier C, **Sala E**, Margarida Cunha T, Bergman A, Brkljacic B, Danza F, Forstner R, Hamm B, Kubik-Huch R, Lopez C, Manfredi R, McHugo J, Oleaga L, Togashi K, Tsili A, Kinkel K. Staging of uterine cervical cancer with MRI: Guidelines of the European Society of Urogenital Radiology. *Eur Radiol*. 2011 May; 21(5):1102-10.

89. DeSouza NM, **Sala E**. Standardizing the use of functional MRI in prostate cancer. *Nat Rev Urol* 2011; 8:127–9.
90. **Sala E**, Rockall A, Kubik-Hunch RA. Advances in Magnetic Resonance Imaging of endometrial cancer. *Eur Radiol*. 2011 Mar; 21(3):468-73.
91. **Sala E**, Rockall A, Rangarajan D, Kubik-Hunch RA. The role of dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging in the female pelvis. *Eur J Radiol* 2010; 76:367– 85.
92. **Sala E**, DeSouza N, Lee S, Atri M, Hricak H. Ovarian Cancer: the role of functional imaging as an endpoint in clinical trials. *Int J Gynecol Cancer*. 2010 Aug; 20(6):971-8.
93. Griffin N, Grant LA, **Sala E**. Adnexal masses: characterization and imaging strategies. *Semin Ultrasound CT MR* 2010; 31(5):330-46.
94. Moyle PM, Addley HC, **Sala E**. Radiological staging of ovarian carcinoma. *Semin Ultrasound CT MR* 2010; 31(5):388-98.
95. Beddy P, Kogan MT, **Sala E**, Griffin N. Magnetic resonance imaging for acute abdominal pain in pregnancy. *Semin Ultrasound CT MR* 2010; 31(5):433-41.
96. Grant LA, **Sala E**, Griffin N. Congenital and acquired abnormalities of the vulva and vagina on magnetic resonance imaging: a pictorial review. *Semin Ultrasound CT MR* 2010; 31(5):347-62.
97. Forstner R, **Sala E**, Kinkel K, Spencer JA. ESUR guidelines: ovarian cancer staging and follow- up. *Eur Radiol* 2010; 20:2773-80.
98. Addley HC, Vargas HA, Moyle PL, Crawford R, **Sala E**. Pelvic imaging following chemotherapy and radiation therapy for gynecologic malignancies. *Radiographics*. 2010 Nov; 30(7):1843-56.
99. Moyle PM, Kataoka MY, Nakai A, Takahata A, Reinhold C, **Sala E**. Non-ovarian cystic lesions of the pelvis. *Radiographics*, 2010; 30 921-938. 2010 Jul-Aug; 30(4):921-38.
100. Addley H, **Sala E**. The role of imaging in advanced endometrial carcinoma. *Eur Oncol*, 2009; 5:68-70.
101. Freeman S, Hampson F, Addley H, Moyle P, **Sala E**. Imaging of the female pelvis. *Obst Gynecol and Rep Med*, 2009; 19:271-81.
102. **Sala E**. Magnetic resonance imaging of female pelvis. *Semin Roentgenol* 2008; 43:290-302.
103. Griffin N, Grant LA, **Sala E**. Magnetic resonance imaging of vaginal and vulval pathology. *Eur Radiol*, 2008; 18:1269-80.
104. **Sala E**, Wakely S, Senior E, Lomas DJ. MRI of malignant neoplasms of uterine corpus and cervix. *Am J Roentgenol* 2007Jun; 188(6):1577-87.
105. Zahra MA, Hollingsworth, K, **Sala E**, Brenton J, Lomas DJ, Tan LT. Dynamic contrast enhanced magnetic resonance imaging as a predictor of tumour response to radiotherapy. *Lancet Oncology*. 2007 Jan; 8(1): 63-74.
106. **Sala E**. Follow-up of ovarian cancer. Making the Best Use of a Department of Clinical Radiology. The Royal College of Radiologists, UK. 2006.
107. Expert Panel on Women's Imaging: Hricak H, Akin O, **Sala E**, Fleischer AC, Böhm-Vélez M, Fishman EK, Mendelson E, Thurmond A, Goldstein S. American College of Radiology. "Invasive cancer of the cervix," ACR Appropriateness Criteria[®], 2005. http://www.acr.org/ac_pda.

108. Expert Panel on Women's imaging: Hricak H, Akin O, **Sala E**, Fleischer AC, Böhm-Vélez M, Fishman EK, Mendelson E, Thurmond A, and Goldstein S. American College of Radiology. "Endometrial cancer of the uterus," ACR Appropriateness Criteria[®], 2005. http://www.acr.org/ac_pda.
109. Huzjan R, **Sala E**, Hricak H. Magnetic resonance imaging and magnetic resonance spectroscopic imaging of prostate cancer. Nat Clin Pract Urol. 2005 Sep; 2 (9):434-42.

Books/Special Issue Guest Editor

1. Shaw A and **Sala E** (Guest Editors). Clinical Radiology Special Issue: Advances in Cancer Imaging. October 2021.
2. Nougaret S, Vargas HA, **Sala E** (Guest Editors). British Journal of Radiology Special Issue: Female genitourinary oncology. August 2021.
3. **Sala E**. Uterus (section ed.) in Hamm B and Ros PR (eds). Abdominal Imaging. Springer-Verlag, Berlin-Heidelberg-New York, 2013.
4. **Sala E**, Freeman AH, Lomas DJ, Ringl H (eds). Radiology for Surgeons in Clinical Practice. Springer-Verlag, Berlin-Heidelberg-New York, 2008.
5. Hricak H, Akin O, **Sala E**, Reinhold C, Ascher S, Levine D (eds). Diagnostic Imaging: Gynaecology. Amirsys Inc, Salt Lake City, Utah, 2007.
6. Freeman AH and **Sala E** (eds). Radiology of Stomach and Duodenum. Springer-Verlag, Berlin-Heidelberg-New York, 2007

Book Chapters

1. Barrett T, Gill AB, **Sala E**. Female Pelvis. In Bammer R (ed) MR and CT Perfusion and Pharmacokinetic Imaging: Clinical Applications and Theoretical Principles. Philadelphia, PA: Wolters Kluwer, 2016; pp867-881.
2. Freeman S, **Sala E**. Imaging in Gynecology. In Bieber E, Sanfilippo J, Horowitz I and Shafi MI (eds) Clinical Gynecology, Cambridge University Press, Cambridge, UK, 2015; pp187-202.
3. **Sala E**, Hricak H. Prostate Carcinoma – Cross sectional imaging techniques. In: Manyak M, Harisingani M, de la Rosette J, Wijkstra H (eds) Imaging in Oncological Urology, Springer-Verlag Berlin-Heidelberg-New York, 2014; pp 229-248.
4. **Sala E**, Freeman S, Ascher SM, Hricak H. Imaging of Gynaecological Malignancies. In: Adam A, Dixon AK, Gillard JH, Schafer-Prokop C. Grainger and Allison Diagnostic Radiology. A textbook of Medical Imaging, Sixth edition, 2014; pp 957-971.
5. **Sala E**, Vargas HA, Donati OF, Weber W, Hricak H. Role of Molecular Imaging in the Era of Personalized Medicine: A Review. In Luna A, Vilanova JC, Hygino Da Cruz JC, Rossi S (eds) Functional Oncological Imaging, Springer-Verlag Berlin-Heidelberg-New York, 2014; pp 43-58.
6. Vargas AH, Barrett T, **Sala E**. Malignant Conditions of the Vulva. In Hamm B and Ros PR (eds). Abdominal Imaging. Springer-Verlag 2013; pp 2175-2182.
7. Barrett T, Vargas AH, **Sala E**. Uterus: Follow-up and Detection of Recurrent Disease. In Hamm B and Ros PR (eds). Abdominal Imaging. Springer-Verlag 2013; pp 2121-2130.

8. Moyle P, **Sala E**. Congenital Uterine Anomalies. In Hamm B and Ros PR (eds). Abdominal Imaging. Springer-Verlag 2013; pp 2063-2076.
9. Burger IA, Freeman SJ, **Sala E**. Uterus: Imaging Techniques and Normal Anatomy. In Hamm B and Ros PR (eds). Abdominal Imaging. Springer-Verlag 2013; pp 2053-2062.
10. Moyle P, **Sala E**. Malignant Neoplasms, Staging of Ovarian Cancer. In Hamm B and Ros PR (eds). Abdominal Imaging. Springer-Verlag 2013; pp 2029-2040.
11. **Sala E**, Lakhman Y, Ma W, Pannu H, Li D, Pandit-Taskar N, Hricak H. Diagnostic Imaging. In: Barakat RR, Berchuck A, Markman M, Randall ME (eds): Principles and Practice of Gynecologic Oncology, 6th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2013; pp 244-283.
12. Barrett T, Vargas HA, **Sala E**. Uterus: Follow-up and detection of recurrent disease. In: Hamm B, Ros PR, eds. Abdominal Imaging. New York, NY: Springer-Verlag Berlin Heidelberg 2012; pp2121-2130.
13. DeSouza NM, **Sala E**, Kyriazi S, Rockall A. Functional imaging: from tumor biology to the clinic. In Kehoe S, Edmondson RJ, Gore M and McNeish IA (eds) Gynaecological Cancers: Biology and Therapeutics. RCOG Press, 2011; pp 183-202.
14. **Sala E**, Reznick R. Female pelvis. In Gourtsoyiannis N (ed) Clinical MRI of the Abdomen: Why, How, When. Berlin-Heidelberg-New York, 2011; pp 535-558.
15. Griffin N, **Sala E**. Imaging in gynaecological oncology. In Shafi MI, Earl H. and Tan LT (eds) Gynaecological Oncology. Cambridge University Press, 2010; pp 51-68.
16. Noel P, **Sala E**, Reinhold C. Imaging of abnormal uterine bleeding. In Morcos S and Thomsen H. (eds) Imaging of the Genitourinary System; Wiley & Sons Ltd, 2009; pp 381-398.
17. Griffin N, **Sala E**, Breeze A, Proctor R. Obstetrics, Gynaecology and Breast. In Graham R and Gallagher F. (eds) Oxford Handbook of Emergencies in Clinical Radiology, Oxford University Press, 2009; pp 305-336.
18. **Sala E**, Hricak H. Reproductive. In Eisenberg RL. and Margulis AR (eds) The Right Imaging Study: A guide for Physicians, Springer-Verlag Berlin-Heidelberg-New York, 2008; pp 516-563.
19. **Sala E** and Hricak H. Female Pelvis. In: Reiser, Semmler and Hricak. Magnetic Resonance Tomography. Springer-Verlag Berlin-Heidelberg-New York, 2007; pp 964-998.
20. Reeders J, Freeman AH, **Sala E**. Radiology-Pathology Correlation. In Freeman AH and **Sala E** (eds) Radiology of Stomach and Duodenum, Springer-Verlag Berlin-Heidelberg-New York, 2007; pp 5-28.
21. **Sala E**, Freeman AH. Conventional Radiology of the Stomach and Duodenum. In Freeman AH and **Sala E** (eds) Radiology of Stomach and Duodenum, Springer-Verlag Berlin-Heidelberg-New York, 2007; pp 89-110.
22. **Sala E**, Freeman AH. The acute Stomach and Duodenum. In Freeman AH and **Sala E** (eds) Radiology of Stomach and Duodenum, Springer-Verlag Berlin-Heidelberg-New York, 2007; pp 217-230.
23. **Sala E**, Allison S, Ascher SM, Hricak H. Imaging in Gynaecology. In: Adam A, Dixon AK (eds). Grainger and Allison's Diagnostic Radiology. A textbook of Medical Imaging, Fifth edition, Edinburgh, 2007; pp 1217-1241.


PATENTS

Kolesnick RN, Haimovitz-Friedman A, **Sala E**, Fuks, Z: US Patent No. 10 413 533 B2, " Enhancement of tumor response to chemotherapy by activation of the ASMase/ceramide pathway through timed administration of a short-acting anti-angiogenic agent"; issued on 17/09/2019.

Spin-Out Company

Co-Founder and CMO of Lucida Medical, 2019

Rome, 14/05/2025

A handwritten signature in black ink, appearing to read "Fala", followed by a horizontal line.